<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Cell Infect Microbiol</journal-id><journal-id journal-id-type="iso-abbrev">Front Cell Infect Microbiol</journal-id><journal-id journal-id-type="pmc-domain-id">1860</journal-id><journal-id journal-id-type="pmc-domain">fcimb</journal-id><journal-id journal-id-type="publisher-id">Front. Cell. Infect. Microbiol.</journal-id><journal-title-group><journal-title>Frontiers in Cellular and Infection Microbiology</journal-title></journal-title-group><issn pub-type="epub">2235-2988</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC5467010</article-id><article-id pub-id-type="pmcid-ver">PMC5467010.1</article-id><article-id pub-id-type="pmcaid">5467010</article-id><article-id pub-id-type="pmcaiid">5467010</article-id><article-id pub-id-type="pmid">28660174</article-id><article-id pub-id-type="doi">10.3389/fcimb.2017.00248</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Microbiology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Parasite Carbohydrate Vaccines</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Jaurigue</surname><given-names initials="JA">Jonnel A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/408992/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Seeberger</surname><given-names initials="PH">Peter H.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="author-notes" rid="fn001"><sup>*</sup></xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/422905/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces</institution><country>Potsdam, Germany</country></aff><aff id="aff2"><sup>2</sup><institution>Institute for Chemistry and Biochemistry, Freie Universit&#228;t Berlin</institution><country>Berlin, Germany</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Brice Rotureau, Institut Pasteur, France</p></fn><fn fn-type="edited-by"><p>Reviewed by: Susu M. Zughaier, Emory University, United States; Charles Kelly, King's College London, United Kingdom; Rashika El Ridi, Cairo University, Egypt</p></fn><corresp id="fn001">*Correspondence: Peter H. Seeberger <email>peter.seeberger@mpikg.mpg.de</email></corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>7</volume><issue-id pub-id-type="pmc-issue-id">284456</issue-id><elocation-id>248</elocation-id><history><date date-type="received"><day>21</day><month>2</month><year>2017</year></date><date date-type="accepted"><day>26</day><month>5</month><year>2017</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2017</year></date></event><event event-type="pmc-live"><date><day>28</day><month>06</month><year>2017</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-05-31 12:25:14.300"><day>31</day><month>05</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2017 Jaurigue and Seeberger.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Jaurigue and Seeberger</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fcimb-07-00248.pdf"/><abstract><p>Vaccination is an efficient means of combating infectious disease burden globally. However, routine vaccines for the world's major human parasitic diseases do not yet exist. Vaccines based on carbohydrate antigens are a viable option for parasite vaccine development, given the proven success of carbohydrate vaccines to combat bacterial infections. We will review the key components of carbohydrate vaccines that have remained largely consistent since their inception, and the success of bacterial carbohydrate vaccines. We will then explore the latest developments for both traditional and non-traditional carbohydrate vaccine approaches for three of the world's major protozoan parasitic diseases&#8212;malaria, toxoplasmosis, and leishmaniasis. The traditional prophylactic carbohydrate vaccine strategy is being explored for malaria. However, given that parasite disease biology is complex and often arises from host immune responses to parasite antigens, carbohydrate vaccines against deleterious immune responses in host-parasite interactions are also being explored. In particular, the highly abundant glycosylphosphatidylinositol molecules specific for <italic toggle="yes">Plasmodium, Toxoplasma</italic>, and <italic toggle="yes">Leishmania</italic> spp. are considered exploitable antigens for this non-traditional vaccine approach. Discussion will revolve around the application of these protozoan carbohydrate antigens for vaccines currently in preclinical development.</p></abstract><kwd-group><kwd>carbohydrate</kwd><kwd>vaccine</kwd><kwd>malaria</kwd><kwd>toxoplasmosis</kwd><kwd>leishmaniasis</kwd></kwd-group><counts><fig-count count="6"/><table-count count="0"/><equation-count count="0"/><ref-count count="136"/><page-count count="12"/><word-count count="9400"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>The first vaccine was the smallpox inoculation introduced in 1796 by Jenner that used whole, attenuated organisms to generate a protective immune response. Our ever-increasing understanding of the underlying immune response that drives vaccination has led to modern subunit vaccines that are formulated to exacting standards. These subunit vaccines use defined protein or carbohydrate antigens implicated in virulence and disease to generate a more directed, nuanced immune response against the offending pathogen.</p><p>Over two centuries of vaccinology has seen significant progress in protection from many viral and bacterial diseases affecting humans such as polio, <italic toggle="yes">Haemophilus influenza</italic> type B, <italic toggle="yes">Streptococcus pneumoniae</italic>, and <italic toggle="yes">Neisseria meningitis</italic>, saving millions of lives each year. And yet, it is disheartening to consider that no vaccine exists for human parasitic infections that continue to cause suffering in many parts of the world (Nyame et al., <xref rid="B96" ref-type="bibr">2004</xref>; Astronomo and Burton, <xref rid="B8" ref-type="bibr">2010</xref>; Hoffman et al., <xref rid="B61" ref-type="bibr">2015</xref>).</p><p>More than a million people die each year from diseases like malaria and leishmaniasis, with lifelong disability, disfigurement, and suffering for those that are living with disease (Hotez et al., <xref rid="B63" ref-type="bibr">2014</xref>). As it stands, diseases caused by protozoan parasites are a leading cause of death the world over yet vaccine strategies for global parasitic diseases such as malaria (John et al., <xref rid="B66" ref-type="bibr">2008</xref>; Seder et al., <xref rid="B113" ref-type="bibr">2013</xref>; Tinto et al., <xref rid="B120" ref-type="bibr">2015</xref>; Gosling and von Seidlein, <xref rid="B52" ref-type="bibr">2016</xref>; WHO, <xref rid="B132" ref-type="bibr">2016b</xref>) and toxoplasmosis (Jongert et al., <xref rid="B67" ref-type="bibr">2009</xref>) have been pursued for decades. The failure in developing an effective vaccine against human parasite infection lies in part to the complexity of parasite biology compared to other microbes (Astronomo and Burton, <xref rid="B8" ref-type="bibr">2010</xref>; Hoffman et al., <xref rid="B61" ref-type="bibr">2015</xref>). Another failure is our relatively poor understanding of the protein and carbohydrate antigens relevant to parasitic virulence. Given that parasite disease pathology often arises from complex host immune responses to parasite antigens, ongoing research to better understand host-parasite interactions in disease is vital to parasite vaccine development (Schofield and Grau, <xref rid="B109" ref-type="bibr">2005</xref>).</p><p>Carbohydrates are considered compelling, exploitable targets for vaccination to overcome the challenges that have prevented the realization of a human parasite vaccine (Nyame et al., <xref rid="B96" ref-type="bibr">2004</xref>; Rodrigues et al., <xref rid="B105" ref-type="bibr">2015</xref>). They are abundantly present on the surface of parasites and play a key role in host-parasite interactions (Rodrigues et al., <xref rid="B105" ref-type="bibr">2015</xref>). Unique carbohydrate antigens characterize multiple developmental stages and tend to be immunoreactive for both protozoan and helminth parasites (Nyame et al., <xref rid="B96" ref-type="bibr">2004</xref>). Adding to the appeal of carbohydrate antigens is the ongoing, systematic characterization of parasite glycobiology regarding their structure, function and biosynthesis (Nyame et al., <xref rid="B96" ref-type="bibr">2004</xref>; Rodrigues et al., <xref rid="B105" ref-type="bibr">2015</xref>). In this review, we will discuss the advantages and disadvantages of modern, carbohydrate antigen-based subunit vaccines, and reflect on the latest developments of carbohydrate vaccines for major protozoan parasites.</p></sec><sec id="s2"><title>Carbohydrate vaccine anatomy</title><sec><title>Carbohydrates antigens</title><p>Carbohydrates are abundant on the surfaces of all cells and exist as poly- and oligosaccharides attached to proteins and lipids (Horlacher and Seeberger, <xref rid="B62" ref-type="bibr">2008</xref>). They are involved in key biological processes such as cell adhesion, modulatory processes, and structural functions (Varki and Lowe, <xref rid="B123" ref-type="bibr">2009</xref>). For pathogenic microbes, carbohydrate interactions are utilized for attachment (Kline et al., <xref rid="B71" ref-type="bibr">2009</xref>) and invasion (de Groot et al., <xref rid="B38" ref-type="bibr">2013</xref>). In turn, pathogenic microbial carbohydrates can be recognized by host immune systems to induce the production of carbohydrate-specific antibodies that can serve protective functions (Astronomo and Burton, <xref rid="B8" ref-type="bibr">2010</xref>). Carbohydrates have been exploited for protective vaccination for decades given their crucial roles in development, growth, and disease (Varki and Lowe, <xref rid="B123" ref-type="bibr">2009</xref>).</p><p>Carbohydrate biosynthesis is not directly template-driven as is the case for nucleic acid and proteins (Rodrigues et al., <xref rid="B105" ref-type="bibr">2015</xref>). Instead, their biosynthesis is a complex, multi-enzymatic process (Delorenzi et al., <xref rid="B39" ref-type="bibr">2002</xref>) forming linear and branched molecules with varied linkages. The result is a class of biopolymers of great complexity and diversity. Their heterogeneity means that access to pure, defined carbohydrates remains a challenge (Liu et al., <xref rid="B80" ref-type="bibr">2006</xref>; Adibekian et al., <xref rid="B2" ref-type="bibr">2011</xref>; Geissner and Seeberger, <xref rid="B49" ref-type="bibr">2016</xref>). Microbial cell culture can be a readily available biological source of carbohydrate antigens, however carbohydrate isolation can be complex and even tedious (Geissner and Seeberger, <xref rid="B49" ref-type="bibr">2016</xref>). Furthermore, isolation is not so straightforward for carbohydrates of low abundance or when microbial culture is not possible. This is especially true for parasites, which generally require more complex culturing conditions compared to bacteria. Fortunately, carbohydrate synthesis technology continues to advance and is increasingly becoming an alternative to biological isolation to source carbohydrates (Anish et al., <xref rid="B5" ref-type="bibr">2014</xref>). Moreover, carbohydrate synthesis allows for pure, completely defined carbohydrate antigens as a basis for synthetic carbohydrate vaccines.</p></sec><sec><title>Carrier proteins</title><p>Virtually all vaccines rely on antibody production and subsequent immunological memory against the target antigen for their protective effect (Zinkernagel, <xref rid="B136" ref-type="bibr">2003</xref>). Accordingly, the immune response against the antigen is a key consideration when it comes to vaccine design where strong, long lasting immune responses are desired. In this regard, proteins and carbohydrates are generally regarded as thymus dependent or thymus independent antigens, respectively, which characterizes the type of antibody immune response they elicit.</p><sec><title>Thymus dependent and thymus independent antigens</title><p>Thymus dependent (TD) antigens, such as proteins, are taken up by antigen presenting cells (APCs). The endocytosed antigen is processed through a series of catalytic steps which liberate small peptide fragments. These peptide fragments form complexes with MHCII molecules and thereby are able to be displayed on the MHCII molecules of the APC. T cells specific to the displayed MHCII-peptide complex are co-stimulated by the APC (Avci and Kasper, <xref rid="B9" ref-type="bibr">2010</xref>). The activated T cells go on to &#8220;help&#8221; the antigen-specific B cells, promoting their proliferation, affinity maturation, antibody isotype switching and long lasting immunological memory (Pulendran and Ahmed, <xref rid="B103" ref-type="bibr">2011</xref>).</p><p>Carbohydrate antigens are classed as thymus independent (TI) antigens and are poorly immunogenic compared to TD antigens (Weintraub, <xref rid="B126" ref-type="bibr">2003</xref>). Carbohydrate antigens are recognized by APCs through pathogen recognition receptors (Blander and Sander, <xref rid="B17" ref-type="bibr">2012</xref>), endocytosed, and processed into oligosaccharide epitopes. These oligosaccharides are not presented on MHCII molecules, but instead are presented directly on the APC cell surface to activate carbohydrate antigen-specific B cells. Due to the lack of T cell activation, B cells are activated in the absence of affinity maturation and isotype switching (Mond et al., <xref rid="B91" ref-type="bibr">1995</xref>) which leads to the predominant production of low affinity IgM antibodies, and only low levels of IgG (Mond and Kokai-Kun, <xref rid="B90" ref-type="bibr">2008</xref>; Astronomo and Burton, <xref rid="B8" ref-type="bibr">2010</xref>; Berti and Adamo, <xref rid="B13" ref-type="bibr">2013</xref>). The IgM antibodies bind in the micromolar range, compared to TD antigen-derived IgG antibodies that bind in the nanomolar range (Broecker et al., <xref rid="B21" ref-type="bibr">2016</xref>; Geissner et al., <xref rid="B48" ref-type="bibr">2016</xref>). B and T cell memory is often not achieved and the immune response is short lived (Adams et al., <xref rid="B1" ref-type="bibr">2008</xref>; Mond and Kokai-Kun, <xref rid="B90" ref-type="bibr">2008</xref>; H&#252;tter and Lepenies, <xref rid="B65" ref-type="bibr">2015</xref>). Moreover, children less than 2 years of age fail to mount an antibody immune response to TI antigens (Weintraub, <xref rid="B126" ref-type="bibr">2003</xref>; Landers et al., <xref rid="B75" ref-type="bibr">2005</xref>).</p></sec><sec><title>Glycoconjugates</title><p>In the 1920s and 1930s, covalent conjugation of carbohydrate antigens to protein scaffolds was first explored to investigate the interaction between the TD antigen properties of proteins with TI carbohydrate antigens (Avery, <xref rid="B11" ref-type="bibr">1931</xref>). This early work formed the basis of the first glycoconjugate carbohydrate vaccines produced in the 1980s (Schneerson et al., <xref rid="B107" ref-type="bibr">1980</xref>; Beuvery et al., <xref rid="B14" ref-type="bibr">1982</xref>; Wessels et al., <xref rid="B127" ref-type="bibr">1993</xref>), where bacterial capsular polysaccharides (CPS) were covalently linked to so-called carrier proteins. Immunization with these CPS-protein glycoconjugates enabled T cell-mediated B cell activation against the target carbohydrate antigen, and induced long term immune memory even in infants (Stein, <xref rid="B117" ref-type="bibr">1992</xref>).</p><p>The mechanism whereby TI carbohydrate antigens can activate the immune system like TD protein antigens via glycoconjugation remains an open area of research. A long-standing mechanistic explanation argues that the carbohydrate-protein conjugate is recognized by carbohydrate-specific B cells. The protein component of the conjugate is subsequently endocytosed, processed and presented on MHCII molecules of the carbohydrate specific B cell. Through the MHCII-peptide complex a peptide-specific T cell can activate the carbohydrate-specific B cell, resulting in TD immune responses against the desired carbohydrate antigen (Figure <xref ref-type="fig" rid="F1">1</xref>; Lucas et al., <xref rid="B81" ref-type="bibr">2005</xref>). A more recently proposed second mechanism argues that after uptake by carbohydrate-specific B cells the glycoconjugate is processed into glycopeptide fragments. Thus, the peptide portion of the fragment can form an MHCII-peptide complex, enabling the simultaneous presentation of the hydrophilic carbohydrate portion to carbohydrate-specific T cells. The T cell interaction activates the presenting B cell accordingly (Avci et al., <xref rid="B10" ref-type="bibr">2011</xref>).</p><fig id="F1" position="float" orientation="portrait"><label>Figure 1</label><caption><p>Proposed mechanism for immune activation of T cells by glycoconjugate vaccines. The carbohydrate-protein conjugate is recognized by carbohydrate-specific B cells. The protein component of the conjugate is subsequently endocytosed, processed and presented on MHCII molecules of the carbohydrate specific B cell in order to activate a T cell for co-stimulation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-07-00248-g0001.jpg"/></fig><p>Five TD carrier proteins are currently used in licensed carbohydrate vaccines (Pichichero, <xref rid="B100" ref-type="bibr">2013</xref>). Of these licensed carrier proteins, a non-toxic mutant of diphtheria toxin (CRM<sub>197</sub>) is often used in vaccine development research for parasitic diseases. Another carrier protein often used in parasite vaccine development is keyhole limpet haemocyanin (KLH). Unlike many other carrier proteins KLH is itself highly glycosylated and is a good promotor of TD and TI responses (Nyame et al., <xref rid="B96" ref-type="bibr">2004</xref>), however it is not licensed for human use.</p><p>The linker conjugating the carrier protein to the carbohydrate antigen is another key consideration of carbohydrate vaccines. Synthetic carbohydrates with defined carrier protein binding sites are advantageous for generating well-defined glycoconjugates with predictable conjugation sites. To minimize the immunogenicity of the linker (Buskas et al., <xref rid="B22" ref-type="bibr">2004</xref>; Gotze et al., <xref rid="B54" ref-type="bibr">2015</xref>) short linkers with no functional groups are best used to ensure that immune responses against the desired antigen epitope are not detrimentally affected. The processing of the linker after uptake by APCs is also an important consideration, to allow for the release of vaccine oligosaccharide and peptide moieties for antigenic display.</p></sec></sec><sec><title>Adjuvants</title><p>Adjuvants are substances that modulate or bolster an effective immune response against the antigens in the vaccine. Formulations are typically emulsions and vesicles that can serve as a delivery vehicle for antigen vaccine components and allow for the slow release of vaccine antigen components over time. Adjuvants can assist antigen immunogenicity by increasing local inflammation and antigen uptake by APCs, and aid in their migration to lymph nodes (Petrovsky and Aguilar, <xref rid="B99" ref-type="bibr">2004</xref>; Di Pasquale et al., <xref rid="B44" ref-type="bibr">2015</xref>). Ideally, adjuvants reduce the amount of antigen or number of immunizations needed for vaccination (Petrovsky and Aguilar, <xref rid="B99" ref-type="bibr">2004</xref>).</p><p>Aluminum-based mineral (Alum) salts served as the only adjuvants for human vaccines for decades (Zimmermann and Lepenies, <xref rid="B135" ref-type="bibr">2015</xref>) and are used for a wide range of vaccines that aim to predominantly induce antibody-mediated immune responses (Bhowmick et al., <xref rid="B15" ref-type="bibr">2014</xref>). Despite its worldwide use, research on its mechanism of action is ongoing (De Gregorio et al., <xref rid="B37" ref-type="bibr">2008</xref>). Today, alum, virosomes, lipid A derived adjuvants, and squalene adjuvants are all in use for human licensed vaccines (Astronomo and Burton, <xref rid="B8" ref-type="bibr">2010</xref>; Di Pasquale et al., <xref rid="B44" ref-type="bibr">2015</xref>; Zimmermann and Lepenies, <xref rid="B135" ref-type="bibr">2015</xref>) and are commonly used in vaccine research. Crude Freund's adjuvant (CFA) is a powerful immunogen often used as an adjuvant for candidate parasite vaccines, but it is not approved for licensed human vaccines.</p><p>Modern vaccines that use better defined, or even synthetic antigens, are generally less immunogenic than crude, whole organism vaccines. Research is ongoing in advancing the efficacy of adjuvant systems for vaccines (Petrovsky and Aguilar, <xref rid="B99" ref-type="bibr">2004</xref>). Many of these new adjuvant systems that are currently being tested in bacterial vaccines are of great interest for adaption to candidate vaccines of parasite diseases. For example, an adjuvant used in animal models, &#945;-GalCer, was covalently attached to <italic toggle="yes">S. pneumoniae</italic> CPS to act as both carrier and adjuvant for the carbohydrate antigen (Cavallari et al., <xref rid="B26" ref-type="bibr">2014</xref>). Endosomal processing by carbohydrate-specific B cells displays &#945;-GalCer antigens via CD1d, stimulating iNKT cells (a class of T cells) to promote B cell hypermutation, class-switching and immunological memory (Cavallari and De Libero, <xref rid="B25" ref-type="bibr">2017</xref>). Zwitterionic polysaccharides (ZPSs) are another emerging class of potentially self-adjuvanting carrier isolated from commensal anaerobic bacteria. ZPSs have the special property of containing one positive and one negative charge on adjacent monosaccharides. When they are processed by APCs this crucially enables their presentation on MHCII complexes, leading to T cell activation. Thus, they are able to activate adaptive immune responses for conjugated carbohydrate antigens in the absence of carrier protein (Berti and Adamo, <xref rid="B13" ref-type="bibr">2013</xref>), leading to the possibility of fully-carbohydrate vaccines (Nishat and Andreana, <xref rid="B95" ref-type="bibr">2016</xref>).</p></sec><sec><title>The success of carbohydrate vaccines</title><p>The concept of carbohydrate antigen vaccines started in the 1920s with the first published evidence that &#8220;residue antigens&#8221; of <italic toggle="yes">Streptococcus pneumoniae</italic> were the CPS of the bacterium (Heidelberger and Avery, <xref rid="B59" ref-type="bibr">1923</xref>, <xref rid="B60" ref-type="bibr">1924</xref>), later demonstrated to be important for virulence and serotype specificity (H&#252;tter and Lepenies, <xref rid="B65" ref-type="bibr">2015</xref>). The CPS of <italic toggle="yes">S. pneumoniae</italic> was shown to produce CPS-specific antibodies (Tillett and Francis, <xref rid="B119" ref-type="bibr">1929</xref>) that protected against the disease symptoms of <italic toggle="yes">S. pneumoniae</italic> (H&#252;tter and Lepenies, <xref rid="B65" ref-type="bibr">2015</xref>), leading to the first CPS antigen vaccine against <italic toggle="yes">S. pneumoniae</italic> in 1947 (Grabenstein and Klugman, <xref rid="B57" ref-type="bibr">2012</xref>). The advent of antibiotics at around the same time somewhat stalled vaccine research, as antibiotics became the preferred method for bacterial disease prevention (Grabenstein and Klugman, <xref rid="B57" ref-type="bibr">2012</xref>; H&#252;tter and Lepenies, <xref rid="B65" ref-type="bibr">2015</xref>). The rise of antibiotic resistance in the following decades (Davies and Davies, <xref rid="B31" ref-type="bibr">2010</xref>) led to a resurgence in carbohydrate vaccine research (Vliegenthart, <xref rid="B125" ref-type="bibr">2006</xref>).</p><p>In the 1970s and 80s, CPS-based vaccines for <italic toggle="yes">S. pneumoniae</italic> were licensed and approved in the USA and Europe. Increasing numbers of strain-specific CPS were added to further itinerations of the vaccine to increase its efficacy, culminating into a 23-valent CPS antigen vaccine first licensed in 1983, protecting vaccinated adults against 87% of <italic toggle="yes">S. pneumoniae</italic> disease in the USA (Grabenstein and Klugman, <xref rid="B57" ref-type="bibr">2012</xref>; Cavallari and De Libero, <xref rid="B25" ref-type="bibr">2017</xref>). Glyconjugate carbohydrate vaccines were later introduced from the 1990s onward to allow for vaccination of broader demographics, especially infants. Glycoconjugate carbohydrate vaccines against disease caused by <italic toggle="yes">H. influenzae</italic> type b infection lead to its virtual elimination within countries with widespread coverage (Lindberg, <xref rid="B78" ref-type="bibr">1999</xref>). Similarly, the use of glycoconjugate vaccines against Neisseria meningitides has also met with effective results (Girard et al., <xref rid="B50" ref-type="bibr">2006</xref>). Vaccines for <italic toggle="yes">S. pneumoniae</italic> are also now glycoconjugates. Several other glycoconjugate vaccines are currently under development, such as a carbohydrate vaccine for group B streptococcus (De Gregorio and Rappuoli, <xref rid="B36" ref-type="bibr">2014</xref>; Lepenies, <xref rid="B77" ref-type="bibr">2015</xref>). Today, glycoconjugate vaccines have substituted pure carbohydrate vaccines where possible, with the most common carrier proteins being CRM<sub>197</sub> and tetanus toxin (Cavallari and De Libero, <xref rid="B25" ref-type="bibr">2017</xref>).</p></sec></sec><sec id="s3"><title>Exploiting carbohydrate antigens for protozoan parasite vaccines</title><p>The key components of CPS carbohydrate vaccines&#8212;antigen, carrier protein, linker, and adjuvant&#8212;have remained largely consistent since their inception. Current parasite vaccine research follows the same component model in this regard. However, as illustrated in the following sections, a recurring theme for carbohydrate parasite vaccines is the need to steer away from traditional prophylactic vaccine development strategies that were successfully applied to bacterial infections.</p><p>In addition to carbohydrate vaccines that can induce sterile protection against the parasite itself, vaccinating against deleterious immune responses in host-parasite interactions is another strategy. Much of the pathology of parasitic disease is due to the host's own immune responses against the parasite. For example, the deadly manifestation of severe malaria is a result of the host's own immune response against parasite-derived molecules, causing the toxic, hyperinflammatory response associated with severe malaria (Boutlis et al., <xref rid="B18" ref-type="bibr">2002</xref>; Krishnegowda et al., <xref rid="B73" ref-type="bibr">2005</xref>; Patel et al., <xref rid="B97" ref-type="bibr">2007</xref>). The <italic toggle="yes">Plasmodium falciparum</italic>-specific glycoform of glycosylphosphatidylinositol (GPI) was identified as the putative toxin implicated in disease (Schofield and Hackett, <xref rid="B110" ref-type="bibr">1993</xref>). GPI molecules are present on the surface of virtually all eukaryotic cells and serve as surface protein anchors, but parasite-specific GPIs occur at relatively high levels in parasitic protozoa (Gowda, <xref rid="B55" ref-type="bibr">2002</xref>). Vaccination strategies aimed at neutralizing the effect of this malaria toxin are being pursued (Schofield, <xref rid="B108" ref-type="bibr">2007</xref>). Similar carbohydrate vaccine strategies for other protozoan parasites are also employed (Buxbaum, <xref rid="B23" ref-type="bibr">2013</xref>). Anti-toxin vaccines have proven successful for other microbial infections, such as the diphtheria toxoid vaccine (Playfair et al., <xref rid="B102" ref-type="bibr">1990</xref>; Schofield, <xref rid="B108" ref-type="bibr">2007</xref>).</p><p>We will explore the latest developments for both traditional and non-traditional carbohydrate vaccine approaches for three of the world's major protozoan parasitic diseases&#8212;malaria, toxoplasmosis, and leishmaniasis.</p><sec><title>Plasmodium</title><p>Malaria is an intra-erythrocytic parasitic disease caused by <italic toggle="yes">Plasmodium</italic> protozoan species. It is among the most devastating infectious diseases of human history and over 3.3 billion people across 97 countries are at risk of infection today (WHO, <xref rid="B129" ref-type="bibr">2013b</xref>, <xref rid="B130" ref-type="bibr">2014</xref>). An estimated 198 million new clinical cases of malaria occur globally with over 80% of new clinical cases occur in sub-saharan Africa alone (WHO, <xref rid="B129" ref-type="bibr">2013b</xref>). Severe malaria disease develops in 5% of <italic toggle="yes">P. falciparum</italic> infections and accounts for 98% of all malaria-related deaths. There are an estimated 584,000 deaths per year attributed to severe disease, mostly young children under the age of 5 (WHO, <xref rid="B129" ref-type="bibr">2013b</xref>). Estimates of severe disease-related deaths are as high as 1.2 million (Murray et al., <xref rid="B93" ref-type="bibr">2012</xref>). Without a vaccine, at least &#8364;2.4 billion are spent annually on malaria control programs using bed nets, insecticides and drug treatments (WHO, <xref rid="B129" ref-type="bibr">2013b</xref>).</p><p>A malaria vaccine should be possible considering that naturally acquired immunity to disease symptoms develops over time. Vaccines against malaria aim to reduce morbidity and mortality, and should be effective in protecting against severe malaria. In the long term, the vaccine should also protect against all clinical disease (WHO, <xref rid="B128" ref-type="bibr">2013a</xref>). To this end, many stages of the parasite lifecycle are targeted by vaccines that decrease parasite load. Examples of some prophylactic vaccines include the whole <italic toggle="yes">P. falciparum</italic> sporozoite vaccine currently in field trials (Seder et al., <xref rid="B113" ref-type="bibr">2013</xref>), and the protein antigen based RTS,S vaccine which is the most advanced example of malaria vaccine currently under development in Phase III (John et al., <xref rid="B66" ref-type="bibr">2008</xref>; Tinto et al., <xref rid="B120" ref-type="bibr">2015</xref>; Gosling and von Seidlein, <xref rid="B52" ref-type="bibr">2016</xref>) and Phase IV trials (WHO, <xref rid="B132" ref-type="bibr">2016b</xref>). At present, the RTS,S vaccine has not been licensed for use as a malaria vaccine (WHO, <xref rid="B131" ref-type="bibr">2016a</xref>).</p><sec><title>Anti-toxin vaccine</title><p>Severe malaria pathology is largely considered to arise from toxic effects of <italic toggle="yes">P. falciparum</italic> GPI (PfGPI), which exists either as protein free glycolipids, or as the major carbohydrate modifications for proteins essential for erythrocyte invasion (Gowda et al., <xref rid="B56" ref-type="bibr">1997</xref>; Schofield and Grau, <xref rid="B109" ref-type="bibr">2005</xref>). PfGPI-specific antibodies are found in adults of malaria-endemic areas, and may be inhibiting the ability of PfGPI to induce the hyper-inflammatory response associated with severe malaria. This is still up for debate, since studies that find an association between PfGPI-specific antibody titer and protection from severe malaria (Brasseur et al., <xref rid="B20" ref-type="bibr">1990</xref>; Naik et al., <xref rid="B94" ref-type="bibr">2000</xref>; Gowda, <xref rid="B55" ref-type="bibr">2002</xref>; Keenihan et al., <xref rid="B69" ref-type="bibr">2003</xref>; Perraut et al., <xref rid="B98" ref-type="bibr">2005</xref>) are balanced by studies that find no such association (de Souza et al., <xref rid="B43" ref-type="bibr">2002</xref>; Boutlis et al., <xref rid="B19" ref-type="bibr">2005</xref>; Cissoko et al., <xref rid="B28" ref-type="bibr">2006</xref>; Gomes et al., <xref rid="B51" ref-type="bibr">2013</xref>; Mbengue et al., <xref rid="B85" ref-type="bibr">2016</xref>). However, PfGPI-specific antibodies are reported to show relevant action in modulating immune responses by protecting immune cells against severe <italic toggle="yes">P. falciparum-</italic>induced inflammatory responses <italic toggle="yes">in-vitro</italic> (Schofield et al., <xref rid="B112" ref-type="bibr">1993</xref>; de Souza et al., <xref rid="B42" ref-type="bibr">2010</xref>).</p><p>To evaluate the effect of using PfGPI in an anti-toxin vaccine, a PfGPI hexasaccharide was synthesized, conjugated to KLH carrier protein and emulsified in CFA (Figure <xref ref-type="fig" rid="F2">2</xref>). C57BL/6 mice were immunized with the glycoconjugate, and then challenged with <italic toggle="yes">P. berghei</italic> ANKA in a mouse model of malaria. Immunization resulted in significant protection against severe malaria, with clearly reduced death rates at 75% survival. The immunized mice were also protected from acidosis, pulmonary oedema, cerebral syndrome and fatality characteristic of the disease model. Apparently, the induction of protective, PfGPI-specific antibodies ameliorated a hyper-inflammatory response against the PfGPI toxin, specifically shown to neutralize the parasite-induced production of TNF-&#945; by macrophages <italic toggle="yes">in vitro</italic>. Furthermore, vaccination did not change parasitaemia levels, demonstrating that the effect of the carbohydrate vaccine candidate was through the neutralization of GPI's toxic effects, rather than interfering with parasite replication (Schofield et al., <xref rid="B111" ref-type="bibr">2002</xref>).</p><fig id="F2" position="float" orientation="portrait"><label>Figure 2</label><caption><p>The <italic toggle="yes">P. falciparum</italic> GPI hexasaccharide of the sequence &#945;-Man-(1-2)-&#945;-[PEtN-6]Man-(1-2)-&#945;-Man(1-6)-&#945;-Man-(1-4)-&#945;-GlcN-(1-6)-<italic toggle="yes">myo</italic>-Ino-1,2-cyclic-phosphate that was chemically synthesized, conjugated to KLH, and used for immunization. The carrier protein was attached to the top PEtN moiety, where PEtN is an abbreviation for phosphoethanolamine. The full PfGPI (in gray) is shown for context, where R groups denote lipid moieties.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-07-00248-g0002.jpg"/></fig><p>Following this work, synthetic PfGPI were utilized as biomarkers to improve our understanding of the PfGPI-specific antibody response (Kamena et al., <xref rid="B68" ref-type="bibr">2008</xref>; Tamborrini et al., <xref rid="B118" ref-type="bibr">2010</xref>). The synthesis of PfGPI molecules continues to be explored (Gurale et al., <xref rid="B58" ref-type="bibr">2016</xref>).</p></sec><sec><title>Sterile immunity vaccine</title><p>In healthy adults, up to 1&#8211;5% of circulating IgG and IgM are specific to the carbohydrate known as &#945;-Gal (Figure <xref ref-type="fig" rid="F3">3</xref>; Macher and Galili, <xref rid="B83" ref-type="bibr">2008</xref>). In contrast to other mammals, humans do not express &#945;-Gal (Galili and Swanson, <xref rid="B47" ref-type="bibr">1991</xref>) allowing for immune reactivity to this carbohydrate (Galili et al., <xref rid="B46" ref-type="bibr">1984</xref>). Exposure to microbiota expressing this glycan drives production of &#945;-Gal-specific antibodies (Macher and Galili, <xref rid="B83" ref-type="bibr">2008</xref>) which are believed to contribute to immune resistance against &#945;-Gal-expressing pathogenic microbes (Bishop and Gagneux, <xref rid="B16" ref-type="bibr">2007</xref>; Cywes-Bentley et al., <xref rid="B30" ref-type="bibr">2013</xref>). <italic toggle="yes">P. falciparum</italic> and other animal model <italic toggle="yes">Plasmodium</italic> spp. express the &#945;-Gal carbohydrate (Galili et al., <xref rid="B45" ref-type="bibr">1998</xref>) possibly bound to GPI-anchored surface proteins (Yilmaz et al., <xref rid="B134" ref-type="bibr">2014</xref>). Early studies already uncovered an association between &#945;-Gal-specific IgM and protection from <italic toggle="yes">P. falciparum</italic> infection in humans. Thus, the effect of immunization on the production of &#945;-Gal-specific antibodies was investigated (Yilmaz et al., <xref rid="B134" ref-type="bibr">2014</xref>).</p><fig id="F3" position="float" orientation="portrait"><label>Figure 3</label><caption><p>The &#945;-gal carbohydrate epitope of the sequence &#945;-Gal-(1-3)-&#946;-Gal-(1-4)-GlcNAc-R that was used as the antigen for generating &#945;-gal-specific antibodies.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-07-00248-g0003.jpg"/></fig><p>Genetically modified mice unable to express &#945;-Gal (Yang et al., <xref rid="B133" ref-type="bibr">1998</xref>) were immunized for the production of &#945;-Gal IgG and IgM. The immunizations were either inoculation with &#945;-Gal expressing <italic toggle="yes">E. coli</italic> bacteria, &#945;-Gal rich rabbit RBCs, or synthetic &#945;-Gal conjugated to BSA. Adjuvants used were CFA and toll-like receptor 9 agonists that enhanced the immunogenicity. The mice were then challenged with <italic toggle="yes">P. berghei</italic> ANKA infection by <italic toggle="yes">Anopheles</italic> mosquito bites. It was found that &#945;-Gal immunization reduced the risk of parasite transmission, thereby providing sterile immunity. This sterile immunity appears to be due to the cytotoxic action of &#945;-Gal specific IgM and subclasses of IgG against the inoculating parasites. Moreover, the antibodies were shown to inhibit hepatocyte transmigration of the parasite (Yilmaz et al., <xref rid="B134" ref-type="bibr">2014</xref>).</p><p>Sterile immunity against malaria infection through the induction of &#945;-Gal-specific antibodies is not similarly present for people living in malaria endemic regions, possibly due to low levels of naturally acquired, protective &#945;-gal-specific antibodies. Promoting a T cell-dependent immune response against the &#945;-Gal carbohydrate was shown to enhance the protective effect of these antibodies in the mouse model (Yilmaz et al., <xref rid="B134" ref-type="bibr">2014</xref>). Moreover, naturally acquired &#945;-gal-specific antibodies may enhance the immunogenicity of antigens enriched with &#945;-gal epitopes by augmenting the T cell response following immunization. This suggests that coupling the &#945;-Gal carbohydrate to existing malaria vaccine candidates could enhance their immunogenicity (Benatuil et al., <xref rid="B12" ref-type="bibr">2005</xref>; Yilmaz et al., <xref rid="B134" ref-type="bibr">2014</xref>). The effect of &#945;-Gal carbohydrate vaccination against other protozoan parasites expressing &#945;-Gal, such as <italic toggle="yes">Trypanosoma</italic> spp. and <italic toggle="yes">Leishmania</italic> spp., may also be considered (Yilmaz et al., <xref rid="B134" ref-type="bibr">2014</xref>).</p></sec></sec><sec><title>Toxoplasma</title><p><italic toggle="yes">Toxoplasma gondii</italic> is found worldwide, capable of infecting nucleated cells of many warm-blooded animals (McLeod et al., <xref rid="B88" ref-type="bibr">2009</xref>; Debierre-Grockiego and Schwarz, <xref rid="B35" ref-type="bibr">2010</xref>) and is estimated to infect half of the world's population (Liu et al., <xref rid="B79" ref-type="bibr">2012</xref>). The disease burden for humans has been well-documented (McLeod et al., <xref rid="B88" ref-type="bibr">2009</xref>). Transmission to humans is either through consumption of food contaminated with tissue cysts and meat products from infected animals or by ingestion of oocysts released in the feces of infected cats (Kijlstra and Jongert, <xref rid="B70" ref-type="bibr">2008</xref>).</p><p>Immunocompetant individuals tolerate <italic toggle="yes">T. gondii</italic> infection which is either asymptomatic or manifest with mild flu-like symptoms. However, the formation of parasite-containing tissue cysts prevents the clearance of the parasite after infection (Montoya and Liesenfeld, <xref rid="B92" ref-type="bibr">2004</xref>). When latent carriers of <italic toggle="yes">T. gondii</italic> are later immunocompromized they are at risk of severe inflammatory reactions in the brain and central nervous system after liberation of the parasites from these cysts (Luft and Remington, <xref rid="B82" ref-type="bibr">1992</xref>). Pregnant women encountering their first infection can also transmit the parasite to the unborn child leading to retardation or abortion (Remington et al., <xref rid="B104" ref-type="bibr">2004</xref>).</p><p>Early vaccination strategies using live parasites (Cutchins and Warren, <xref rid="B29" ref-type="bibr">1956</xref>) and fixed parasites (Krahenbuhl et al., <xref rid="B72" ref-type="bibr">1972</xref>) protected from subsequent challenge. Today, vaccines against toxoplasmosis aim to limit acute parasitemia, protect against congenital toxoplasmosis, reduce the number of tissue cysts, or lessen parasite transmission (Kur et al., <xref rid="B74" ref-type="bibr">2009</xref>). To date, sterile immunity against <italic toggle="yes">T. gondii</italic> has not been achieved (Jongert et al., <xref rid="B67" ref-type="bibr">2009</xref>). A live vaccine for veterinary toxoplasmosis exists to give limited protection during pregnancy (Buxton and Innes, <xref rid="B24" ref-type="bibr">1995</xref>) but is not approved for human use and does not fully eliminate the parasite (Liu et al., <xref rid="B79" ref-type="bibr">2012</xref>).</p><sec><title>GPI vaccine</title><p>Glycolipid GPI anchors of <italic toggle="yes">T. gondii</italic> (TgGPI) have been considered as possible vaccine antigens due to their effect in modulating inflammatory TNF-&#945; responses against the parasite (Debierre-Grockiego, <xref rid="B32" ref-type="bibr">2010</xref>). In 2015, TgGPI were explored as possible vaccine candidates for the first time.</p><p>GPI anchors are highly abundant on <italic toggle="yes">T. gondii</italic> (~10<sup>6</sup> copies per cell) (Tsai et al., <xref rid="B122" ref-type="bibr">2012</xref>) and exist as a protein-attached or protein-free glycoform (Figure <xref ref-type="fig" rid="F4">4</xref>). Both glycoforms induce inflammatory reactions like macrophage TNF-&#945; production (Debierre-Grockiego et al., <xref rid="B33" ref-type="bibr">2003</xref>) through TLR-2 and TLR-4 signaling (Debierre-Grockiego et al., <xref rid="B34" ref-type="bibr">2007</xref>), which exacerbates toxoplasmosis in mice (Hunter et al., <xref rid="B64" ref-type="bibr">1996</xref>). A vaccine that induces TgGPI-specific antibodies could ameliorate TgGPI-mediated inflammatory effects and lower disease burden (Debierre-Grockiego, <xref rid="B32" ref-type="bibr">2010</xref>).</p><fig id="F4" position="float" orientation="portrait"><label>Figure 4</label><caption><p>The <italic toggle="yes">T. gondii</italic> GPI of the sequence &#945;-Man-(1-2)-&#945;-Man-(1-6)-&#945;-Man-(1-4)-&#945;-GlcN-(1-6)-<italic toggle="yes">myo</italic>-Ino with lipid moiety. Glycoform 1R bears a &#945;-Glc(1-4)-&#946;-GalNAc side chain, while glycoform 2R lacks the glucose moiety.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-07-00248-g0004.jpg"/></fig><p>The two major TgGPI glycoforms were synthethized and covalently conjugated to CRM<sub>197</sub>. BALB/c mice were then immunized with either one of the glycoconjugates before challenge with virulent <italic toggle="yes">T. gondii</italic> RH strain. Immunization did not provide protection for mice in the lethal challenge model. Furthermore, the induced antibodies failed to exhibit any significant effect on the inflammatory response for either group (Gotze et al., <xref rid="B54" ref-type="bibr">2015</xref>). Analysis of the immune response indicates that antibody induction was directed away from the desired carbohydrate side branch of the TgGPI, and more toward the linker used to attach the carbohydrate to the carrier protein. In a potential next step, the formulation has to be adjusted (Gotze et al., <xref rid="B54" ref-type="bibr">2015</xref>).</p><p>Ongoing research utilizing synthetic TgGPI molecules has helped to identify biomarkers of acute and latent infection. During acute infection, high levels of TgGPI-specific IgM and IgG are present, while latent infection shows a reduced IgM response (Gotze et al., <xref rid="B53" ref-type="bibr">2014</xref>).</p></sec></sec><sec><title>Leishmania</title><p>There are two million new cases of leishmaniasis every year as the disease is increasingly becoming a worldwide health burden (Desjeux, <xref rid="B41" ref-type="bibr">2004</xref>). The vector borne, facultative intracellular parasite (Chappuis et al., <xref rid="B27" ref-type="bibr">2007</xref>) enters mononuclear, phagocytotic cells such as macrophages. Cutaneous leishmaniasis is the most common form of disease, notable for skin ulcers that result in disability and scarring for the infected patient (Seeberger, <xref rid="B114" ref-type="bibr">2007</xref>; WHO, <xref rid="B132a" ref-type="bibr">2017</xref>). <italic toggle="yes">Leishmania donovani</italic> causes visceral leishmaniasis and is the most severe form of disease characterized by fever, substantial weight loss, anemia, swelling of liver and spleen, and possible death. It is believed to be second only to malaria in terms of fatal infection (Seeberger, <xref rid="B114" ref-type="bibr">2007</xref>; Aebischer, <xref rid="B3" ref-type="bibr">2014</xref>). Patients are treated with antimony drugs which are costly, toxic and increasingly ineffective against resistant parasite strains. A vaccine against leishmaniasis is a desirable, economic strategy to combat this disease (Lee et al., <xref rid="B76" ref-type="bibr">2012</xref>; Singh et al., <xref rid="B115" ref-type="bibr">2016</xref>).</p><p>A cocktail of heat-killed <italic toggle="yes">Leishmania</italic> parasites is a clinically tested vaccine. However, the efficacy of the vaccine to prevent disease is not confirmed (Armijos et al., <xref rid="B6" ref-type="bibr">2004</xref>; Velez et al., <xref rid="B124" ref-type="bibr">2005</xref>). Other attempts involving killed or attenuated parasites for leishmanial vaccine development have not resulted in a licensed vaccine (Topuzogullari et al., <xref rid="B121" ref-type="bibr">2013</xref>).</p><sec><title>Vaccine efforts</title><p><italic toggle="yes">Leishmania</italic> parasites express lipophosphoglycans (LPG) on their cell surface. This molecule is composed of a GPI anchor, a repeating phosphorylated disaccharide fragment, and variable cap oligosaccharides (Seeberger, <xref rid="B114" ref-type="bibr">2007</xref>). The LPGs are important for survival and virulence of the parasite (Spath et al., <xref rid="B116" ref-type="bibr">2000</xref>) and vaccination preparations with purified LPG is protective against cutaneous leishmaniasis (McConville et al., <xref rid="B86" ref-type="bibr">1987</xref>; Russell and Alexander, <xref rid="B106" ref-type="bibr">1988</xref>; Moll et al., <xref rid="B89" ref-type="bibr">1989</xref>). Regarding the variable capping oligosaccharide, a unique capping tetrasaccharide (Figure <xref ref-type="fig" rid="F5">5</xref>) was identified as vital for parasite invasion of macrophages (Descoteaux and Turco, <xref rid="B40" ref-type="bibr">2002</xref>) and was the key component of a synthetic carbohydrate vaccine for leishmaniasis (Liu et al., <xref rid="B80" ref-type="bibr">2006</xref>).</p><fig id="F5" position="float" orientation="portrait"><label>Figure 5</label><caption><p>The general structure of the capping tetrasaccharide &#945;-Man-(1-2)-&#945;-Man-(1-2)-[&#946;-Gal-(1-4)]-&#945;-Man of <italic toggle="yes">Leishmania</italic> LPG. This oligosaccharide is attached to phosphoglycan repeating units, followed by a GPI anchor.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-07-00248-g0005.jpg"/></fig><p>The capping oligosaccharide moiety of LPG was synthesized in initial immunological studies exploiting this antigen for vaccination. The carbohydrate was loaded onto virosomes that served as an integrated carrier and adjuvant, before being used to immunize BALB/c mice. Oligosaccharide-specific IgM and IgG1 responses were produced, indicating that the immune response to the carbohydrate antigen was T cell-dependent. Furthermore, the antibodies against the synthetic carbohydrate were cross-reactive with natural carbohydrate antigens of <italic toggle="yes">Leishmania</italic> parasites indicating its possible utility as a vaccine antigen (Liu et al., <xref rid="B80" ref-type="bibr">2006</xref>). A further study immunized BALB/c mice with synthetic LPG capping oligosaccharides conjugated to CRM<sub>197</sub> and emulsified in CFA. This vaccine candidate produced IgG antibodies specific for the parasite. The oligosaccharides were used to evaluate immune responses of infected humans and dogs as the basis for a diagnostic test (Anish et al., <xref rid="B4" ref-type="bibr">2013</xref>). Given the carbohydrate vaccines currently in production, animal model challenge studies to test the protective effect of these synthetic molecules is the next logical step.</p><p>LPG vaccination to protect against cutaneous leishmaniasis employed animal challenge studies that evaluated the LPG component of whole <italic toggle="yes">L. amazonensis</italic> antigen (LaAg). It was known that intramuscular, systemic immunization of LaAg results in deleterious disease outcomes after challenge, however LPG depletion rendered LaAg protective against <italic toggle="yes">Leishmania</italic> infection with respect to lesion growth and parasite load compared to non-depleted LaAg. This indicated that LPG was the component responsible for deleterious effects of LaAg inoculation. During further investigations, mice were intranasally vaccinated with LPG alone to determine whether intranasal vaccination of the disease-promoting component could promote protection against cutaneous leishmaniasis (Pinheiro et al., <xref rid="B101" ref-type="bibr">2007</xref>). Intranasal vaccination with LPG was protective, and provided further evidence for the potential of utilizing LPG in a carbohydrate antigen vaccine that would protect against cutaneous leishmaniasis.</p><p>Recently, the role of <italic toggle="yes">L. mexicana</italic> protein-free GPI molecules (GIPL) in disease has been elucidated, shedding more light on immunologic pathways affecting glycolipid-specific antibody responses (Figure <xref ref-type="fig" rid="F6">6</xref>). After it was determined that <italic toggle="yes">L. mexicana</italic> infection induces GIPL-specific IgG1 responses, a monoclonal antibody against GIPL was shown to bind to the surface of parasites, and promote IL-10 production in macrophages co-cultured with parasite. Production of IL-10 is deleterious as it blocks an effective immune response that is needed to kill parasites and resolve skin lesions in cutaneous leishmaniasis. In humans, GIPL-specific antibodies are produced in response to infection with cutaneous leishmaniasis. Opsonization of parasites with these antibodies was shown to promote deleterious IL-10 production in macrophages. The role of GIPL-specific antibodies in both mouse and humans opens the possibility of generating a carbohydrate vaccine that can induce competing, non-pathogenic antibody isotypes that can protect against <italic toggle="yes">L. mexicana</italic> infection (Buxbaum, <xref rid="B23" ref-type="bibr">2013</xref>).</p><fig id="F6" position="float" orientation="portrait"><label>Figure 6</label><caption><p>The <italic toggle="yes">L. mexicana</italic> GIPLs contain the sequence PEtN-6-&#945;-Man-(1-2)-&#945;-Man-(1-6)-&#945;-Man-(1-4)-&#945;-GlcN-(1-6)-<italic toggle="yes">myo</italic>-Ino-2-phosphate attached to a lipid base that anchors into the membrane (McConville et al., <xref rid="B87" ref-type="bibr">1993</xref>). PEtN is an abbreviation for phosphoethanolamine. Additions to this base sequence are found for many of the GIPLs. Note the structure of the carbohydrate chain is the same as the sequence of protein-free <italic toggle="yes">P. falciparum</italic> GPI anchors (Assis et al., <xref rid="B7" ref-type="bibr">2012</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-07-00248-g0006.jpg"/></fig></sec></sec></sec><sec id="s4"><title>Concluding remarks</title><p>Carbohydrate vaccines represent a promising application of glycobiology to human health. The immense successes of bacterial CPS vaccines should, in theory, be similarly achievable with parasite carbohydrate vaccines. With continued advances in parasite culture handling, and carbohydrate synthesis technologies, it is a great time to apply the development strategies employed for bacterial CPS vaccine research to parasite carbohydrate vaccine research.</p></sec><sec id="s5"><title>Author contributions</title><p>JJ contributed to the drafting of the article. PS and JJ contributed to all revisions of the article.</p><sec><title>Conflict of interest statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></sec></body><back><ack><p>The authors gratefully acknowledge Paulina Kaplonek for critically editing the manuscript.</p></ack><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> The authors thank the Max-Planck Society for generous financial support. JJ is funded by DFG Research Training Group Parasite Infections (GRK 2046).</p></fn></fn-group><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adams</surname><given-names>E. W.</given-names></name><name name-style="western"><surname>Ratner</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name><name name-style="western"><surname>Hacohen</surname><given-names>N.</given-names></name></person-group> (<year>2008</year>). <article-title>Carbohydrate-mediated targeting of antigen to dendritic cells leads to enhanced presentation of antigen to T cells</article-title>. <source>Chembiochem</source><volume>9</volume>, <fpage>294</fpage>&#8211;<lpage>303</lpage>. <pub-id pub-id-type="doi">10.1002/cbic.200700310</pub-id><pub-id pub-id-type="pmid">18186095</pub-id><pub-id pub-id-type="pmcid">PMC2700842</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adibekian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stallforth</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hecht</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Werz</surname><given-names>D. B.</given-names></name><name name-style="western"><surname>Gagneux</surname><given-names>P.</given-names></name><name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name></person-group> (<year>2011</year>). <article-title>Comparative bioinformatics analysis of the mammalian and bacterial glycomes</article-title>. <source>Chem. Sci.</source><volume>2</volume>, <fpage>337</fpage>&#8211;<lpage>344</lpage>. <pub-id pub-id-type="doi">10.1039/C0SC00322K</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aebischer</surname><given-names>T.</given-names></name></person-group> (<year>2014</year>). <article-title><italic toggle="yes">Leishmania</italic> spp. proteome data sets: a comprehensive resource for vaccine development to target visceral leishmaniasis</article-title>. <source>Front. Immun.</source><volume>5</volume>:<fpage>260</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2014.00260</pub-id><pub-id pub-id-type="pmid">24959165</pub-id><pub-id pub-id-type="pmcid">PMC4050426</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anish</surname><given-names>C.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Wahlbrink</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bogdan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ntais</surname><given-names>P.</given-names></name><name name-style="western"><surname>Antoniou</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Immunogenicity and diagnostic potential of synthetic antigenic cell surface glycans of leishmania</article-title>. <source>Acs Chem. Biol.</source><volume>8</volume>, <fpage>2412</fpage>&#8211;<lpage>2422</lpage>. <pub-id pub-id-type="doi">10.1021/cb400602k</pub-id><pub-id pub-id-type="pmid">24004239</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anish</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schumann</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name></person-group> (<year>2014</year>). <article-title>Chemical biology approaches to designing defined carbohydrate vaccines</article-title>. <source>Chem. Biol.</source><volume>21</volume>, <fpage>38</fpage>&#8211;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/j.chembiol.2014.01.002</pub-id><pub-id pub-id-type="pmid">24439205</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Armijos</surname><given-names>R. X.</given-names></name><name name-style="western"><surname>Weigel</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Calvopina</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hidalgo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cevallos</surname><given-names>W.</given-names></name><name name-style="western"><surname>Correa</surname><given-names>J.</given-names></name></person-group> (<year>2004</year>). <article-title>Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against new world cutaneous leishmaniasis</article-title>. <source>Vaccine</source><volume>22</volume>, <fpage>1320</fpage>&#8211;<lpage>1326</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2003.06.002</pub-id><pub-id pub-id-type="pmid">15003662</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Assis</surname><given-names>R. R.</given-names></name><name name-style="western"><surname>Ibraim</surname><given-names>I. C.</given-names></name><name name-style="western"><surname>Noronha</surname><given-names>F. S.</given-names></name><name name-style="western"><surname>Turco</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Soares</surname><given-names>R. P.</given-names></name></person-group> (<year>2012</year>). <article-title>Glycoinositolphospholipids from <italic toggle="yes">Leishmania braziliensis</italic> and <italic toggle="yes">L. infantum</italic>: modulation of innate immune system and variations in carbohydrate structure</article-title>. <source>PLoS Negl. Trop. Dis.</source><volume>6</volume>:<fpage>e1543</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0001543</pub-id><pub-id pub-id-type="pmid">22389743</pub-id><pub-id pub-id-type="pmcid">PMC3289616</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Astronomo</surname><given-names>R. D.</given-names></name><name name-style="western"><surname>Burton</surname><given-names>D. R.</given-names></name></person-group> (<year>2010</year>). <article-title>Carbohydrate vaccines: developing sweet solutions to sticky situations?</article-title><source>Nat Rev. Drug Discov</source><volume>9</volume>, <fpage>308</fpage>&#8211;<lpage>324</lpage>. <pub-id pub-id-type="doi">10.1038/nrd3012</pub-id><pub-id pub-id-type="pmid">20357803</pub-id><pub-id pub-id-type="pmcid">PMC3878310</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avci</surname><given-names>F. Y.</given-names></name><name name-style="western"><surname>Kasper</surname><given-names>D. L.</given-names></name></person-group> (<year>2010</year>). <article-title>How bacterial carbohydrates influence the adaptive immune system</article-title>. <source>Annu. Rev. Immun.</source><volume>28</volume>, <fpage>107</fpage>&#8211;<lpage>130</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-immunol-030409-101159</pub-id><pub-id pub-id-type="pmid">19968562</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avci</surname><given-names>F. Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X. M.</given-names></name><name name-style="western"><surname>Tsuji</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kasper</surname><given-names>D. L.</given-names></name></person-group> (<year>2011</year>). <article-title>A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design</article-title>. <source>Nat. Med.</source><volume>17</volume>, <fpage>1602</fpage>&#8211;<lpage>1609</lpage>. <pub-id pub-id-type="doi">10.1038/nm.2535</pub-id><pub-id pub-id-type="pmid">22101769</pub-id><pub-id pub-id-type="pmcid">PMC3482454</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avery</surname><given-names>O. T.</given-names></name></person-group> (<year>1931</year>). <article-title>Chemo-immunological studies on conjugated carbohydrate-proteins: V. the immunological specifity of an antigen prepared by combining the capsular polysaccharide of type III pneumococcus with foreign protein</article-title>. <source>J. Exp. Med.</source><volume>54</volume>, <fpage>437</fpage>&#8211;<lpage>447</lpage>. <pub-id pub-id-type="pmid">19869930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.54.3.437</pub-id><pub-id pub-id-type="pmcid">PMC2132011</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benatuil</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kaye</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rich</surname><given-names>R. F.</given-names></name><name name-style="western"><surname>Fishman</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Green</surname><given-names>W. R.</given-names></name><name name-style="western"><surname>Iacomini</surname><given-names>J.</given-names></name></person-group> (<year>2005</year>). <article-title>The influence of natural antibody specificity on antigen immunogenicity</article-title>. <source>Eur. J. Immun.</source><volume>35</volume>, <fpage>2638</fpage>&#8211;<lpage>2647</lpage>. <pub-id pub-id-type="doi">10.1002/eji.200526146</pub-id><pub-id pub-id-type="pmid">16082726</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Adamo</surname><given-names>R.</given-names></name></person-group> (<year>2013</year>). <article-title>Recent mechanistic insights on glycoconjugate vaccines and future perspectives</article-title>. <source>ACS Chem. Biol.</source><volume>8</volume>, <fpage>1653</fpage>&#8211;<lpage>1663</lpage>. <pub-id pub-id-type="doi">10.1021/cb400423g</pub-id><pub-id pub-id-type="pmid">23841819</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beuvery</surname><given-names>E. C.</given-names></name><name name-style="western"><surname>Vanrossum</surname><given-names>F.</given-names></name><name name-style="western"><surname>Nagel</surname><given-names>J.</given-names></name></person-group> (<year>1982</year>). <article-title>Comparison of the induction of immunoglobulin-M and immunoglobulin-G antibodies in mice with purified pneumococcal type-3 and meningococcal group-C polysaccharides and their protein conjugates</article-title>. <source>Infect. Immun.</source><volume>37</volume>, <fpage>15</fpage>&#8211;<lpage>22</lpage>. <pub-id pub-id-type="pmid">6809623</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.37.1.15-22.1982</pub-id><pub-id pub-id-type="pmcid">PMC347483</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhowmick</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ravindran</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>N.</given-names></name></person-group> (<year>2014</year>). <article-title>IL-4 contributes to failure, and colludes with IL-10 to exacerbate <italic toggle="yes">Leishmania donovani</italic> infection following administration of a subcutaneous leishmanial antigen vaccine</article-title>. <source>BMC Microbiol.</source><volume>14</volume>:<fpage>8</fpage><pub-id pub-id-type="doi">10.1186/1471-2180-14-8</pub-id><pub-id pub-id-type="pmid">24428931</pub-id><pub-id pub-id-type="pmcid">PMC3897895</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bishop</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Gagneux</surname><given-names>P.</given-names></name></person-group> (<year>2007</year>). <article-title>Evolution of carbohydrate antigens &#8212; microbial forces shaping host glycomes?</article-title><source>Glycobiology</source><volume>17</volume>, <fpage>23R</fpage>&#8211;<lpage>34R</lpage>. <pub-id pub-id-type="doi">10.1093/glycob/cwm005</pub-id><pub-id pub-id-type="pmid">17237137</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blander</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Sander</surname><given-names>L. E.</given-names></name></person-group> (<year>2012</year>). <article-title>Beyond pattern recognition: five immune checkpoints for scaling the microbial threat</article-title>. <source>Nat. Rev. Immun.</source><volume>12</volume>, <fpage>215</fpage>&#8211;<lpage>225</lpage>. <pub-id pub-id-type="doi">10.1038/nri3167</pub-id><pub-id pub-id-type="pmid">22362354</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boutlis</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Gowda</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Naik</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Maguire</surname><given-names>G. P.</given-names></name><name name-style="western"><surname>Mgone</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Bockarie</surname><given-names>M. J.</given-names></name><etal/></person-group>. (<year>2002</year>). <article-title>Antibodies to <italic toggle="yes">Plasmodium falciparum</italic> glycosylphosphatidylinositols: inverse association with tolerance of parasitemia in Papua New Guinean children and adults</article-title>. <source>Infect. Immun.</source><volume>70</volume>, <fpage>5052</fpage>&#8211;<lpage>5057</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.70.9.5052-5057.2002</pub-id><pub-id pub-id-type="pmid">12183552</pub-id><pub-id pub-id-type="pmcid">PMC128285</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boutlis</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Riley</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Anstey</surname><given-names>N. M.</given-names></name><name name-style="western"><surname>de Souza</surname><given-names>J. B.</given-names></name></person-group> (<year>2005</year>). <article-title>Glycosylphosphatidylinositols in malaria pathogenesis and immunity: potential for therapeutic inhibition and vaccination</article-title>. <source>Curr. Top Microbiol. Immunol.</source><volume>297</volume>, <fpage>145</fpage>&#8211;<lpage>185</lpage>. <pub-id pub-id-type="doi">10.1007/3-540-29967-x_5</pub-id><pub-id pub-id-type="pmid">16265905</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brasseur</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ballet</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Druilhe</surname><given-names>P.</given-names></name></person-group> (<year>1990</year>). <article-title>Impairment of <italic toggle="yes">Plasmodium-falciparum</italic>-specific antibody-response in severe malaria</article-title>. <source>J. Clin. Microbiol.</source><volume>28</volume>, <fpage>265</fpage>&#8211;<lpage>268</lpage>. <pub-id pub-id-type="pmid">2179259</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/jcm.28.2.265-268.1990</pub-id><pub-id pub-id-type="pmcid">PMC269588</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Broecker</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hanske</surname><given-names>J.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Baek</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Wahlbrink</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wojcik</surname><given-names>F.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Multivalent display of minimal Clostridium difficile glycan epitopes mimics antigenic properties of larger glycans</article-title>. <source>Nat. Commun.</source><volume>7</volume>:<fpage>11224</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms11224</pub-id><pub-id pub-id-type="pmid">27091615</pub-id><pub-id pub-id-type="pmcid">PMC4838876</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buskas</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y. H.</given-names></name><name name-style="western"><surname>Boons</surname><given-names>G. J.</given-names></name></person-group> (<year>2004</year>). <article-title>The immunogenicity of the tumor-associated antigen Lewis(y) may be suppressed by a bifunctional cross-linker required for coupling to a carrier protein</article-title>. <source>Chem. Eur. J.</source><volume>10</volume>, <fpage>3517</fpage>&#8211;<lpage>3524</lpage>. <pub-id pub-id-type="doi">10.1002/chem.200400074</pub-id><pub-id pub-id-type="pmid">15252797</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buxbaum</surname><given-names>L. U.</given-names></name></person-group> (<year>2013</year>). <article-title>Leishmania mexicana infection induces igg to parasite surface glycoinositol phospholipids that can induce il-10 in mice and humans</article-title>. <source>PLoS Negl. Trop. Dis.</source><volume>7</volume>:<fpage>e2224</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0002224</pub-id><pub-id pub-id-type="pmid">23675550</pub-id><pub-id pub-id-type="pmcid">PMC3649955</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buxton</surname><given-names>D.</given-names></name><name name-style="western"><surname>Innes</surname><given-names>E. A.</given-names></name></person-group> (<year>1995</year>). <article-title>A commercial vaccine for ovine toxoplasmosis</article-title>. <source>Parasitology</source><volume>110</volume>, <fpage>S11</fpage>&#8211;<lpage>S16</lpage>. <pub-id pub-id-type="doi">10.1017/S003118200000144X</pub-id><pub-id pub-id-type="pmid">7784124</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cavallari</surname><given-names>M.</given-names></name><name name-style="western"><surname>De Libero</surname><given-names>G.</given-names></name></person-group> (<year>2017</year>). <article-title>From immunologically archaic to neoteric glycovaccines</article-title>. <source>Vaccines</source><volume>5</volume>:<fpage>4</fpage>. <pub-id pub-id-type="doi">10.3390/vaccines5010004</pub-id><pub-id pub-id-type="pmid">28134792</pub-id><pub-id pub-id-type="pmcid">PMC5371740</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cavallari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stallforth</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kalinichenko</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rathwell</surname><given-names>D. C. K.</given-names></name><name name-style="western"><surname>Gronewold</surname><given-names>T. M. A.</given-names></name><name name-style="western"><surname>Adibekian</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>A semisynthetic carbohydrate-lipid vaccine that protects against S-pneumoniae in mice</article-title>. <source>Nat. Chem. Biol.</source><volume>10</volume>, <fpage>950</fpage>&#8211;<lpage>956</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.1650</pub-id><pub-id pub-id-type="pmid">25282505</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chappuis</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sundar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hailu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ghalib</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rijal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Peeling</surname><given-names>R. W.</given-names></name><etal/></person-group>. (<year>2007</year>). <article-title>Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?</article-title><source>Nat. Rev. Microbiol.</source><volume>5</volume>, <fpage>873</fpage>&#8211;<lpage>882</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro1748</pub-id><pub-id pub-id-type="pmid">17938629</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cissoko</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Daou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lyke</surname><given-names>K. E.</given-names></name><name name-style="western"><surname>Dicko</surname><given-names>A.</given-names></name><name name-style="western"><surname>Diarra</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kone</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2006</year>). <article-title>Serum antibody levels to glycosylphosphatidylinositols in specimens derived from matched Malian children with severe or uncomplicated <italic toggle="yes">Plasmodium falciparum</italic> malaria and healthy controls</article-title>. <source>Am. J. Trop. Med. Hyg.</source><volume>75</volume>, <fpage>199</fpage>&#8211;<lpage>204</lpage>. <pub-id pub-id-type="pmid">16896119</pub-id><pub-id pub-id-type="pmcid">PMC2738947</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cutchins</surname><given-names>E. C.</given-names></name><name name-style="western"><surname>Warren</surname><given-names>J.</given-names></name></person-group> (<year>1956</year>). <article-title>Immunity patterns in the Guinea Pig following Toxoplasma infection and vaccination with killed Toxoplasma</article-title>. <source>Am. J. Trop. Med. Hyg.</source><volume>5</volume>, <fpage>197</fpage>&#8211;<lpage>209</lpage>. <pub-id pub-id-type="doi">10.4269/ajtmh.1956.5.197</pub-id><pub-id pub-id-type="pmid">13302615</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cywes-Bentley</surname><given-names>C.</given-names></name><name name-style="western"><surname>Skurnik</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zaidi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Roux</surname><given-names>D.</given-names></name><name name-style="western"><surname>DeOliveira</surname><given-names>R. B.</given-names></name><name name-style="western"><surname>Garrett</surname><given-names>W. S.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Antibody to a conserved antigenic target is protective against diverse prokaryotic and eukaryotic pathogens</article-title>. <source>Proc. Nat. Acad. Sci. U.S.A.</source><volume>110</volume>, <fpage>E2209</fpage>&#8211;<lpage>E2218</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1303573110</pub-id><pub-id pub-id-type="pmid">23716675</pub-id><pub-id pub-id-type="pmcid">PMC3683766</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>J.</given-names></name><name name-style="western"><surname>Davies</surname><given-names>D.</given-names></name></person-group> (<year>2010</year>). <article-title>Origins and evolution of antibiotic resistance</article-title>. <source>Microbiol. Mol. Biol. Rev.</source><volume>74</volume>, <fpage>417</fpage>&#8211;<lpage>433</lpage>. <pub-id pub-id-type="doi">10.1128/MMBR.00016-10</pub-id><pub-id pub-id-type="pmid">20805405</pub-id><pub-id pub-id-type="pmcid">PMC2937522</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Debierre-Grockiego</surname><given-names>F.</given-names></name></person-group> (<year>2010</year>). <article-title>Glycolipids are potential targets for protozoan parasite diseases</article-title>. <source>Trends Parasitol.</source><volume>26</volume>, <fpage>404</fpage>&#8211;<lpage>411</lpage>. <pub-id pub-id-type="doi">10.1016/j.pt.2010.04.006</pub-id><pub-id pub-id-type="pmid">20483663</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Debierre-Grockiego</surname><given-names>F.</given-names></name><name name-style="western"><surname>Azzouz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dubremetz</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Geyer</surname><given-names>H.</given-names></name><name name-style="western"><surname>Geyer</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2003</year>). <article-title>Roles of glycosylphosphatidylinositols of Toxoplasma gondii - induction of tumor necrosis factor-alpha production in macrophages</article-title>. <source>J. Biol. Chem.</source><volume>278</volume>, <fpage>32987</fpage>&#8211;<lpage>32993</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M304791200</pub-id><pub-id pub-id-type="pmid">12815041</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Debierre-Grockiego</surname><given-names>F.</given-names></name><name name-style="western"><surname>Campos</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Azzouz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bieker</surname><given-names>U.</given-names></name><name name-style="western"><surname>Resende</surname><given-names>A. G.</given-names></name><etal/></person-group>. (<year>2007</year>). <article-title>Activation of TLR2 and TLR4 by glycosylphosphatidylinositols derived from Toxoplasma gondii</article-title>. <source>J. Immunol.</source><volume>179</volume>, <fpage>1129</fpage>&#8211;<lpage>1137</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.179.2.1129</pub-id><pub-id pub-id-type="pmid">17617606</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Debierre-Grockiego</surname><given-names>F.</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>R. T.</given-names></name></person-group> (<year>2010</year>). <article-title>Immunological reactions in response to apicomplexan glycosylphosphatidylinositols</article-title>. <source>Glycobiology</source><volume>20</volume>, <fpage>801</fpage>&#8211;<lpage>811</lpage>. <pub-id pub-id-type="doi">10.1093/glycob/cwq038</pub-id><pub-id pub-id-type="pmid">20378610</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Gregorio</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name></person-group> (<year>2014</year>). <article-title>From empiricism to rational design: a personal perspective of the evolution of vaccine development</article-title>. <source>Nat. Rev. Immunol.</source><volume>14</volume>, <fpage>505</fpage>&#8211;<lpage>514</lpage>. <pub-id pub-id-type="doi">10.1038/nri3694</pub-id><pub-id pub-id-type="pmid">24925139</pub-id><pub-id pub-id-type="pmcid">PMC7096907</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Gregorio</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tritto</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name></person-group> (<year>2008</year>). <article-title>Alum adjuvanticity: unraveling a century old mystery</article-title>. <source>Eur. J. Immunol.</source><volume>38</volume>, <fpage>2068</fpage>&#8211;<lpage>2071</lpage>. <pub-id pub-id-type="doi">10.1002/eji.200838648</pub-id><pub-id pub-id-type="pmid">18651701</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Groot</surname><given-names>P. W. J.</given-names></name><name name-style="western"><surname>Bader</surname><given-names>O.</given-names></name><name name-style="western"><surname>de Boer</surname><given-names>A. D.</given-names></name><name name-style="western"><surname>Weig</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chauhan</surname><given-names>N.</given-names></name></person-group> (<year>2013</year>). <article-title>Adhesins in human fungal pathogens: glue with plenty of stick</article-title>. <source>Eukaryotic Cell</source><volume>12</volume>, <fpage>470</fpage>&#8211;<lpage>481</lpage>. <pub-id pub-id-type="doi">10.1128/EC.00364-12</pub-id><pub-id pub-id-type="pmid">23397570</pub-id><pub-id pub-id-type="pmcid">PMC3623432</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delorenzi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sexton</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shams-Eldin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>R. T.</given-names></name><name name-style="western"><surname>Speed</surname><given-names>T.</given-names></name><name name-style="western"><surname>Schofield</surname><given-names>L.</given-names></name></person-group> (<year>2002</year>). <article-title>Genes for glycosylphosphatidylinositol toxin biosynthesis in <italic toggle="yes">Plasmodium falciparum</italic></article-title>. <source>Infect. Immun.</source><volume>70</volume>, <fpage>4510</fpage>&#8211;<lpage>4522</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.70.8.4510-4522.2002</pub-id><pub-id pub-id-type="pmid">12117963</pub-id><pub-id pub-id-type="pmcid">PMC128142</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Descoteaux</surname><given-names>A.</given-names></name><name name-style="western"><surname>Turco</surname><given-names>S. J.</given-names></name></person-group> (<year>2002</year>). <article-title>Functional aspects of the <italic toggle="yes">Leishmania donovani</italic> lipophosphoglycan during macrophage infection</article-title>. <source>Microb. Infect.</source><volume>4</volume>, <fpage>975</fpage>&#8211;<lpage>981</lpage>. <pub-id pub-id-type="doi">10.1016/S1286-4579(02)01624-6</pub-id><pub-id pub-id-type="pmid">12106791</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desjeux</surname><given-names>P.</given-names></name></person-group> (<year>2004</year>). <article-title>Leishmaniasis: current situation and new perspectives</article-title>. <source>Comp. Immunol. Microbiol. Infect. Dis.</source><volume>27</volume>, <fpage>305</fpage>&#8211;<lpage>318</lpage>. <pub-id pub-id-type="doi">10.1016/j.cimid.2004.03.004</pub-id><pub-id pub-id-type="pmid">15225981</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Souza</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Runglall</surname><given-names>M.</given-names></name><name name-style="western"><surname>Corran</surname><given-names>P. H.</given-names></name><name name-style="western"><surname>Okell</surname><given-names>L. C.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gowda</surname><given-names>D. C.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Neutralization of malaria glycosylphosphatidylinositol <italic toggle="yes">in vitro</italic> by serum IgG from malaria-exposed individuals</article-title>. <source>Infect. Immun.</source><volume>78</volume>, <fpage>3920</fpage>&#8211;<lpage>3929</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.00359-10</pub-id><pub-id pub-id-type="pmid">20566691</pub-id><pub-id pub-id-type="pmcid">PMC2937451</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Souza</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Todd</surname><given-names>J.</given-names></name><name name-style="western"><surname>Krishegowda</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gowda</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Kwiatkowski</surname><given-names>D.</given-names></name><name name-style="western"><surname>Riley</surname><given-names>E. M.</given-names></name></person-group> (<year>2002</year>). <article-title>Prevalence and boosting of antibodies to <italic toggle="yes">Plasmodium falciparum</italic> glycosylphosphatidylinositols and evaluation of their association with protection from mild and severe clinical malaria</article-title>. <source>Infect. Immun.</source><volume>70</volume>, <fpage>5045</fpage>&#8211;<lpage>5051</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.70.9.5045-5051.2002</pub-id><pub-id pub-id-type="pmid">12183551</pub-id><pub-id pub-id-type="pmcid">PMC128284</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di Pasquale</surname><given-names>A.</given-names></name><name name-style="western"><surname>Preiss</surname><given-names>S.</given-names></name><name name-style="western"><surname>Da Silva</surname><given-names>F. T.</given-names></name><name name-style="western"><surname>Garcon</surname><given-names>N.</given-names></name></person-group> (<year>2015</year>). <article-title>Vaccine adjuvants: from 1920 to 2015 and beyond</article-title>. <source>Vaccines</source><volume>3</volume>, <fpage>320</fpage>&#8211;<lpage>343</lpage>. <pub-id pub-id-type="doi">10.3390/vaccines3020320</pub-id><pub-id pub-id-type="pmid">26343190</pub-id><pub-id pub-id-type="pmcid">PMC4494348</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galili</surname><given-names>U.</given-names></name><name name-style="western"><surname>LaTemple</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Radic</surname><given-names>M. Z.</given-names></name></person-group> (<year>1998</year>). <article-title>A sensitive assay for measuring alpha-gal epitope expression on cells by a monoclonal anti-Gal antibody</article-title>. <source>Transplantation</source><volume>65</volume>, <fpage>1129</fpage>&#8211;<lpage>1132</lpage>. <pub-id pub-id-type="doi">10.1097/00007890-199804270-00020</pub-id><pub-id pub-id-type="pmid">9583877</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galili</surname><given-names>U.</given-names></name><name name-style="western"><surname>Rachmilewitz</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Peleg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Flechner</surname><given-names>I.</given-names></name></person-group> (<year>1984</year>). <article-title>A unique natural human-igg antibody with anti-alpha-galactosyl specificity</article-title>. <source>J. Exp. Med.</source><volume>160</volume>, <fpage>1519</fpage>&#8211;<lpage>1531</lpage>. <pub-id pub-id-type="doi">10.1084/jem.160.5.1519</pub-id><pub-id pub-id-type="pmid">6491603</pub-id><pub-id pub-id-type="pmcid">PMC2187506</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galili</surname><given-names>U.</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>K.</given-names></name></person-group> (<year>1991</year>). <article-title>Gene-sequences suggest inactivation of alpha-1,3-galactosyltransferase in catarrhines after the divergence of apes from monkeys</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>88</volume>, <fpage>7401</fpage>&#8211;<lpage>7404</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.88.16.7401</pub-id><pub-id pub-id-type="pmid">1908095</pub-id><pub-id pub-id-type="pmcid">PMC52303</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geissner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Leddermann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Anish</surname><given-names>C.</given-names></name><name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name></person-group> (<year>2016</year>). <article-title>Deciphering antigenic determinants of <italic toggle="yes">Streptococcus pneumoniae</italic> serotype 4 capsular polysaccharide using synthetic oligosaccharides</article-title>. <source>ACS Chem. Biol.</source><volume>11</volume>, <fpage>335</fpage>&#8211;<lpage>344</lpage>. <pub-id pub-id-type="doi">10.1021/acschembio.5b00768</pub-id><pub-id pub-id-type="pmid">26674834</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geissner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name></person-group> (<year>2016</year>). <article-title>Glycan arrays: from basic biochemical research to bioanalytical and biomedical applications</article-title>. <source>Annu. Rev. Anal. Chem.</source><volume>9</volume>, <fpage>223</fpage>&#8211;<lpage>247</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-anchem-071015-041641</pub-id><pub-id pub-id-type="pmid">27306309</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Girard</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Preziosi</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Aguado</surname><given-names>M. T.</given-names></name><name name-style="western"><surname>Kieny</surname><given-names>M. P.</given-names></name></person-group> (<year>2006</year>). <article-title>A review of vaccine research and development: meningococcal disease</article-title>. <source>Vaccine</source><volume>24</volume>, <fpage>4692</fpage>&#8211;<lpage>4700</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2006.03.034</pub-id><pub-id pub-id-type="pmid">16621189</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomes</surname><given-names>L. R.</given-names></name><name name-style="western"><surname>Totino</surname><given-names>P. R.</given-names></name><name name-style="western"><surname>Sanchez</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Daniel</surname><given-names>E. P.</given-names></name><name name-style="western"><surname>Macedo</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Fortes</surname><given-names>F.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Asymptomatic infection in individuals from the municipality of Barcelos, (Brazilian Amazon) is not associated with the anti-<italic toggle="yes">Plasmodium falciparum</italic> glycosylphosphatidylinositol antibody response</article-title>. <source>Mem. Inst. Oswaldo Cruz</source><volume>108</volume>, <fpage>796</fpage>&#8211;<lpage>800</lpage>. <pub-id pub-id-type="doi">10.1590/0074-0276108062013018</pub-id><pub-id pub-id-type="pmid">24037204</pub-id><pub-id pub-id-type="pmcid">PMC3970686</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gosling</surname><given-names>R.</given-names></name><name name-style="western"><surname>von Seidlein</surname><given-names>L.</given-names></name></person-group> (<year>2016</year>). <article-title>The future of the RTS, S/AS01 malaria vaccine: an alternative development plan</article-title>. <source>PLoS Med.</source><volume>13</volume>:<fpage>e1001994</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pmed.1001994</pub-id><pub-id pub-id-type="pmid">27070151</pub-id><pub-id pub-id-type="pmcid">PMC4829262</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gotze</surname><given-names>S.</given-names></name><name name-style="western"><surname>Azzouz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>Y. H.</given-names></name><name name-style="western"><surname>Gross</surname><given-names>U.</given-names></name><name name-style="western"><surname>Reinhardt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Anish</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Diagnosis of toxoplasmosis using a synthetic glycosylphosphatidylinositol glycan</article-title>. <source>Angew. Chem. Int. Ed Engl.</source><volume>53</volume>, <fpage>13701</fpage>&#8211;<lpage>13705</lpage>. <pub-id pub-id-type="doi">10.1002/anie.201406706</pub-id><pub-id pub-id-type="pmid">25323101</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gotze</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reinhardt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Geissner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Azzouz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>Y. H.</given-names></name><name name-style="western"><surname>Kurucz</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Investigation of the protective properties of glycosylphosphatidylinositol-based vaccine candidates in a Toxoplasma gondii mouse challenge model</article-title>. <source>Glycobiology</source><volume>25</volume>, <fpage>984</fpage>&#8211;<lpage>991</lpage>. <pub-id pub-id-type="doi">10.1093/glycob/cwv040</pub-id><pub-id pub-id-type="pmid">26044798</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gowda</surname><given-names>D. C.</given-names></name></person-group> (<year>2002</year>). <article-title>Structure and activity of glycosylphosphatidylinositol anchors of <italic toggle="yes">Plasmodium falciparum</italic></article-title>. <source>Microb. Infect.</source><volume>4</volume>, <fpage>983</fpage>&#8211;<lpage>990</lpage>. <pub-id pub-id-type="doi">10.1016/S1286-4579(02)01619-2</pub-id><pub-id pub-id-type="pmid">12106792</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gowda</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>P.</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>E. A.</given-names></name></person-group> (<year>1997</year>). <article-title>Glycosylphosphatidylinositol anchors represent the major carbohydrate modification in proteins of intraerythrocytic stage <italic toggle="yes">Plasmodium falciparum</italic></article-title>. <source>J. Biol. Chem.</source><volume>272</volume>, <fpage>6428</fpage>&#8211;<lpage>6439</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.272.10.6428</pub-id><pub-id pub-id-type="pmid">9045667</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grabenstein</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Klugman</surname><given-names>K. P.</given-names></name></person-group> (<year>2012</year>). <article-title>A century of pneumococcal vaccination research in humans</article-title>. <source>Clin. Microbiol. Infect.</source><volume>18</volume>, <fpage>15</fpage>&#8211;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1111/j.1469-0691.2012.03943.x</pub-id><pub-id pub-id-type="pmid">22882735</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gurale</surname><given-names>B. P.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>X. K.</given-names></name><name name-style="western"><surname>Dinh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dhawane</surname><given-names>A. N.</given-names></name><name name-style="western"><surname>Lucchi</surname><given-names>N. W.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Toward the development of the next generation of a rapid diagnostic test: synthesis of glycophosphatidylinositol, (GPI) analogues of <italic toggle="yes">plasmodium falciparum</italic> and immunological characterization</article-title>. <source>Bioconjug. Chem.</source><volume>27</volume>, <fpage>2886</fpage>&#8211;<lpage>2899</lpage>. <pub-id pub-id-type="doi">10.1021/acs.bioconjchem.6b00542</pub-id><pub-id pub-id-type="pmid">27792303</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heidelberger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Avery</surname><given-names>O. T.</given-names></name></person-group> (<year>1923</year>). <article-title>The soluble specific substance of pneumococcus</article-title>. <source>J. Exp. Med.</source><volume>38</volume>, <fpage>0073</fpage>&#8211;<lpage>0079</lpage>. <pub-id pub-id-type="doi">10.1084/jem.38.1.73</pub-id><pub-id pub-id-type="pmid">19868772</pub-id><pub-id pub-id-type="pmcid">PMC2128423</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heidelberger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Avery</surname><given-names>O. T.</given-names></name></person-group> (<year>1924</year>). <article-title>The soluble specific substance of pneumococcus second paper</article-title>. <source>J. Exp. Med.</source><volume>40</volume>, <fpage>301</fpage>&#8211;<lpage>316</lpage>. <pub-id pub-id-type="doi">10.1084/jem.40.3.301</pub-id><pub-id pub-id-type="pmid">19868919</pub-id><pub-id pub-id-type="pmcid">PMC2128576</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffman</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Vekemans</surname><given-names>J.</given-names></name><name name-style="western"><surname>Richie</surname><given-names>T. L.</given-names></name><name name-style="western"><surname>Duffy</surname><given-names>P. E.</given-names></name></person-group> (<year>2015</year>). <article-title>The march toward malaria vaccines</article-title>. <source>Vaccine</source><volume>33</volume>, <fpage>D13</fpage>&#8211;<lpage>D23</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2015.07.091</pub-id><pub-id pub-id-type="pmid">26324116</pub-id><pub-id pub-id-type="pmcid">PMC5634526</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horlacher</surname><given-names>T.</given-names></name><name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name></person-group> (<year>2008</year>). <article-title>Carbohydrate arrays as tools for research and diagnostics</article-title>. <source>Chem. Soc. Rev.</source><volume>37</volume>, <fpage>1414</fpage>&#8211;<lpage>1422</lpage>. <pub-id pub-id-type="doi">10.1039/b708016f</pub-id><pub-id pub-id-type="pmid">18568167</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hotez</surname><given-names>P. J.</given-names></name><name name-style="western"><surname>Alvarado</surname><given-names>M.</given-names></name><name name-style="western"><surname>Basanez</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Bolliger</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bourne</surname><given-names>R.</given-names></name><name name-style="western"><surname>Boussinesq</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases</article-title>. <source>PLoS Neglected Trop. Dis.</source><volume>8</volume>:<fpage>e2865</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0002865</pub-id><pub-id pub-id-type="pmid">25058013</pub-id><pub-id pub-id-type="pmcid">PMC4109880</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hunter</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Subauste</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Remington</surname><given-names>J. S.</given-names></name></person-group> (<year>1996</year>). <article-title>Cells and cytokines in resistance to Toxoplasma gondii</article-title>. <source>Toxoplasma Gondii</source><volume>219</volume>, <fpage>113</fpage>&#8211;<lpage>125</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-642-51014-4_11</pub-id><pub-id pub-id-type="pmid">8791694</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>H&#252;tter</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lepenies</surname><given-names>B.</given-names></name></person-group> (<year>2015</year>). <article-title>Carbohydrate-based vaccines: an overview</article-title>. <source>Methods Mol. Biol.</source><volume>1331</volume>, <fpage>1</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4939-2874-3_1</pub-id><pub-id pub-id-type="pmid">26169731</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>John</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Tande</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Moormann</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Sumba</surname><given-names>P. O.</given-names></name><name name-style="western"><surname>Lanar</surname><given-names>D. E.</given-names></name><name name-style="western"><surname>Min</surname><given-names>X. M.</given-names></name><etal/></person-group>. (<year>2008</year>). <article-title>Antibodies to pre-erythrocytic <italic toggle="yes">Plasmodium falciparum</italic> antigens and risk of clinical malaria in Kenyan children</article-title>. <source>J. Infect. Dis.</source><volume>197</volume>, <fpage>519</fpage>&#8211;<lpage>526</lpage>. <pub-id pub-id-type="doi">10.1086/526787</pub-id><pub-id pub-id-type="pmid">18275273</pub-id><pub-id pub-id-type="pmcid">PMC2607240</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jongert</surname><given-names>E.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>C. W.</given-names></name><name name-style="western"><surname>Gargano</surname><given-names>N.</given-names></name><name name-style="western"><surname>Forster-Wald</surname><given-names>E.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>E.</given-names></name></person-group> (<year>2009</year>). <article-title>Vaccines against Toxoplasma gondii: challenges and opportunities</article-title>. <source>Mem. Inst. Oswaldo Cruz</source><volume>104</volume>, <fpage>252</fpage>&#8211;<lpage>266</lpage>. <pub-id pub-id-type="doi">10.1590/S0074-02762009000200019</pub-id><pub-id pub-id-type="pmid">19430651</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamena</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tamborrini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>Y. U.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pluschke</surname><given-names>G.</given-names></name><etal/></person-group>. (<year>2008</year>). <article-title>Synthetic GPI array to study antitoxic malaria response</article-title>. <source>Nat. Chem. Biol.</source><volume>4</volume>, <fpage>238</fpage>&#8211;<lpage>240</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.75</pub-id><pub-id pub-id-type="pmid">18311131</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keenihan</surname><given-names>S. N. H.</given-names></name><name name-style="western"><surname>Ratiwayanto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Soebianto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Krisin</surname></name><name name-style="western"><surname>Marwoto</surname><given-names>H.</given-names></name><name name-style="western"><surname>Krishnegowda</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Age-dependent impairment of IgG responses to glycosylphosphatidylinositol with equal exposure to <italic toggle="yes">Plasmodium falciparum</italic> among Javanese migrants to Papua, Indonesia</article-title>. <source>Am. J. Trop. Med. Hygiene</source><volume>69</volume>, <fpage>36</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="pmid">12932094</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kijlstra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jongert</surname><given-names>E.</given-names></name></person-group> (<year>2008</year>). <article-title>Control of the risk of human toxoplasmosis transmitted by meat</article-title>. <source>Int. J. Parasitol.</source><volume>38</volume>, <fpage>1359</fpage>&#8211;<lpage>1370</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijpara.2008.06.002</pub-id><pub-id pub-id-type="pmid">18694755</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kline</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Falker</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dahlberg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Normark</surname><given-names>S.</given-names></name><name name-style="western"><surname>Henriques-Normark</surname><given-names>B.</given-names></name></person-group> (<year>2009</year>). <article-title>Bacterial adhesins in host-microbe interactions</article-title>. <source>Cell Host Microb.</source><volume>5</volume>, <fpage>580</fpage>&#8211;<lpage>592</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2009.05.011</pub-id><pub-id pub-id-type="pmid">19527885</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krahenbuhl</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Remington</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Ruskin</surname><given-names>J.</given-names></name></person-group> (<year>1972</year>). <article-title>Use of killed vaccines in immunization against an intracellular parasite - Toxoplasma-gondii</article-title>. <source>J. Immunol.</source><volume>108</volume>, <fpage>425</fpage>&#8211;<lpage>431</lpage>. <pub-id pub-id-type="pmid">5049090</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krishnegowda</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hajjar</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Douglass</surname><given-names>E. J.</given-names></name><name name-style="western"><surname>Uematsu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2005</year>). <article-title>Induction of proinflammatory responses in macrophages by the glycosylphosphatidylinositols of <italic toggle="yes">Plasmodium falciparum</italic>: cell signaling receptors, glycosylphosphatidylinositol, (GPI) structural requirement, and regulation of GPI activity</article-title>. <source>J. Biol. Chem.</source><volume>280</volume>, <fpage>8606</fpage>&#8211;<lpage>8616</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M413541200</pub-id><pub-id pub-id-type="pmid">15623512</pub-id><pub-id pub-id-type="pmcid">PMC4984258</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kur</surname><given-names>J.</given-names></name><name name-style="western"><surname>Holec-Gasior</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hiszczynska-Sawicka</surname><given-names>E.</given-names></name></person-group> (<year>2009</year>). <article-title>Current status of toxoplasmosis vaccine development</article-title>. <source>Expert Rev. Vaccines</source><volume>8</volume>, <fpage>791</fpage>&#8211;<lpage>808</lpage>. <pub-id pub-id-type="doi">10.1586/erv.09.27</pub-id><pub-id pub-id-type="pmid">19485758</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Landers</surname><given-names>C. D.</given-names></name><name name-style="western"><surname>Chelvarajan</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Bondada</surname><given-names>S.</given-names></name></person-group> (<year>2005</year>). <article-title>The role of B cells and accessory cells in the neonatal response to TI-2 antigens</article-title>. <source>Immunol. Res.</source><volume>31</volume>, <fpage>25</fpage>&#8211;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1385/IR:31:1:25</pub-id><pub-id pub-id-type="pmid">15591620</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>B. Y.</given-names></name><name name-style="western"><surname>Bacon</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kitchen</surname><given-names>S. B.</given-names></name><name name-style="western"><surname>Connor</surname><given-names>D. L.</given-names></name><name name-style="western"><surname>Slayton</surname><given-names>R. B.</given-names></name></person-group> (<year>2012</year>). <article-title>The Economic value of a visceral leishmaniasis vaccine in Bihar State, India</article-title>. <source>Am. J. Trop. Med. Hygiene</source><volume>86</volume>, <fpage>417</fpage>&#8211;<lpage>425</lpage>. <pub-id pub-id-type="doi">10.4269/ajtmh.2012.10-0415</pub-id><pub-id pub-id-type="pmid">22403311</pub-id><pub-id pub-id-type="pmcid">PMC3284356</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lepenies</surname><given-names>B.</given-names></name></person-group> (<year>2015</year>). <article-title>Carbohydrate-based vaccines preface</article-title>. <source>Methods Mol. Biol.</source><volume>1331</volume>, <fpage>v</fpage>&#8211;<lpage>vi</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4939-2874-3</pub-id><pub-id pub-id-type="pmid">26378288</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindberg</surname><given-names>A. A.</given-names></name></person-group> (<year>1999</year>). <article-title>Glycoprotein conjugate vaccines</article-title>. <source>Vaccine</source><volume>17</volume>, <fpage>S28</fpage>&#8211;<lpage>S36</lpage>. <pub-id pub-id-type="doi">10.1016/s0264-410x(99)00232-7</pub-id><pub-id pub-id-type="pmid">10506406</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Das Singla</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H. Y.</given-names></name></person-group> (<year>2012</year>). <article-title>Vaccines against Toxoplasma gondii Status, challenges and future directions</article-title>. <source>Hum. Vaccin. Immunother.</source><volume>8</volume>, <fpage>1305</fpage>&#8211;<lpage>1308</lpage>. <pub-id pub-id-type="doi">10.4161/hv.21006</pub-id><pub-id pub-id-type="pmid">22906945</pub-id><pub-id pub-id-type="pmcid">PMC3579912</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X. Y.</given-names></name><name name-style="western"><surname>Siegrist</surname><given-names>S.</given-names></name><name name-style="western"><surname>Amacker</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zurbriggen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pluschke</surname><given-names>G.</given-names></name><name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name></person-group> (<year>2006</year>). <article-title>Enhancement of the immunogenicity of synthetic carbohydrates by conjugation to virosomes: a leishmaniasis vaccine candidate</article-title>. <source>ACS Chem. Biol.</source><volume>1</volume>, <fpage>161</fpage>&#8211;<lpage>164</lpage>. <pub-id pub-id-type="doi">10.1021/cb600086b</pub-id><pub-id pub-id-type="pmid">17163663</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lucas</surname><given-names>A. H.</given-names></name><name name-style="western"><surname>Apicella</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>C. E.</given-names></name></person-group> (<year>2005</year>). <article-title>Carbohydrate moieties as vaccine candidates</article-title>. <source>Clin. Infect. Dis.</source><volume>41</volume>, <fpage>705</fpage>&#8211;<lpage>712</lpage>. <pub-id pub-id-type="doi">10.1086/432582</pub-id><pub-id pub-id-type="pmid">16080094</pub-id><pub-id pub-id-type="pmcid">PMC7107877</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luft</surname><given-names>B. J.</given-names></name><name name-style="western"><surname>Remington</surname><given-names>J. S.</given-names></name></person-group> (<year>1992</year>). <article-title>Toxoplasmic encephalitis in aids</article-title>. <source>Clin. Infect. Dis.</source><volume>15</volume>, <fpage>211</fpage>&#8211;<lpage>222</lpage>. <pub-id pub-id-type="doi">10.1093/clinids/15.2.211</pub-id><pub-id pub-id-type="pmid">1520757</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macher</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Galili</surname><given-names>U.</given-names></name></person-group> (<year>2008</year>). <article-title>The Gal alpha 1,3Gal beta 1,4GlcNAc-R, (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance</article-title>. <source>Biochim. Biophys. Acta</source><volume>1780</volume>, <fpage>75</fpage>&#8211;<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbagen.2007.11.003</pub-id><pub-id pub-id-type="pmid">18047841</pub-id><pub-id pub-id-type="pmcid">PMC2271034</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mbengue</surname><given-names>B.</given-names></name><name name-style="western"><surname>Niang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Niang</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Varela</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Fall</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fall</surname><given-names>M. M.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Inflammatory cytokine and humoral responses to<italic toggle="yes">Plasmodium falciparum</italic>glycosylphosphatidylinositols correlates with malaria immunity and pathogenesis</article-title>. <source>Immun. Inflam. Dis.</source><volume>4</volume>, <fpage>24</fpage>&#8211;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1002/iid3.89</pub-id><pub-id pub-id-type="pmid">27042299</pub-id><pub-id pub-id-type="pmcid">PMC4768067</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McConville</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Bacic</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>G. F.</given-names></name><name name-style="western"><surname>Handman</surname><given-names>E.</given-names></name></person-group> (<year>1987</year>). <article-title>Lipophosphoglycan of leishmania-major that vaccinates against cutaneous leishmaniasis contains an alkylglycerophosphoinositol lipid anchor</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>84</volume>, <fpage>8941</fpage>&#8211;<lpage>8945</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.84.24.8941</pub-id><pub-id pub-id-type="pmid">3480520</pub-id><pub-id pub-id-type="pmcid">PMC299667</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McConville</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Collidge</surname><given-names>T. A. C.</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>M. A. J.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>P.</given-names></name></person-group> (<year>1993</year>). <article-title>The glycoinositol phospholipids of Leishmania-Mexicana promastigotes. Evidence for the presence of 3 distinct pathways of glycolipid biosynthesis</article-title>. <source>J. Biol. Chem.</source><volume>268</volume>, <fpage>15595</fpage>&#8211;<lpage>15604</lpage>. <pub-id pub-id-type="pmid">8340385</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McLeod</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kieffer</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sautter</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hosten</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pelloux</surname><given-names>H.</given-names></name></person-group> (<year>2009</year>). <article-title>Why prevent, diagnose and treat congenital toxoplasmosis?</article-title><source>Mem. Inst. Oswaldo Cruz</source><volume>104</volume>, <fpage>320</fpage>&#8211;<lpage>344</lpage>. <pub-id pub-id-type="pmid">19430661</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1590/s0074-02762009000200029</pub-id><pub-id pub-id-type="pmcid">PMC2735102</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moll</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>G. F.</given-names></name><name name-style="western"><surname>McConville</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Handman</surname><given-names>E.</given-names></name></person-group> (<year>1989</year>). <article-title>Evidence for T-Cell Recognition in Mice of a Purified Lipophosphoglycan from Leishmania-Major</article-title>. <source>Infect. Immun.</source><volume>57</volume>, <fpage>3349</fpage>&#8211;<lpage>3356</lpage>. <pub-id pub-id-type="pmid">2807527</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.57.11.3349-3356.1989</pub-id><pub-id pub-id-type="pmcid">PMC259819</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mond</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Kokai-Kun</surname><given-names>J. F.</given-names></name></person-group> (<year>2008</year>). <article-title>The multifunctional role of antibodies in the protective response to bacterial T cell-independent antigens</article-title>. <source>Spec. Complement. Hum. Immun Respon. Infect.</source><volume>319</volume>, <fpage>17</fpage>&#8211;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-540-73900-5_2</pub-id><pub-id pub-id-type="pmid">18080413</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mond</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Lees</surname><given-names>A.</given-names></name><name name-style="western"><surname>Snapper</surname><given-names>C. M.</given-names></name></person-group> (<year>1995</year>). <article-title>T-cell-independent antigens type-2</article-title>. <source>Annu. Rev. Immunol.</source><volume>13</volume>, <fpage>655</fpage>&#8211;<lpage>692</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.iy.13.040195.003255</pub-id><pub-id pub-id-type="pmid">7612238</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montoya</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>Liesenfeld</surname><given-names>O.</given-names></name></person-group> (<year>2004</year>). <article-title>Toxoplasmosis</article-title>. <source>Lancet</source><volume>363</volume>, <fpage>1965</fpage>&#8211;<lpage>1976</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(04)16412-X</pub-id><pub-id pub-id-type="pmid">15194258</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murray</surname><given-names>C. J. L.</given-names></name><name name-style="western"><surname>Rosenfeld</surname><given-names>L. C.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>K. G.</given-names></name><name name-style="western"><surname>Foreman</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Haring</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Global malaria mortality between 1980 and 2010: a systematic analysis</article-title>. <source>Lancet</source><volume>379</volume>, <fpage>413</fpage>&#8211;<lpage>431</lpage>. <pub-id pub-id-type="pmid">22305225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(12)60034-8</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naik</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Branch</surname><given-names>O. H.</given-names></name><name name-style="western"><surname>Woods</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Vijaykumar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Perkins</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Nahlen</surname><given-names>B. L.</given-names></name><etal/></person-group>. (<year>2000</year>). <article-title>Glycosylphosphatidylinositol anchors of <italic toggle="yes">Plasmodium falciparum</italic>: molecular characterization and naturally elicited antibody response that may provide immunity to malaria pathogenesis</article-title>. <source>J. Exp. Med.</source><volume>192</volume>, <fpage>1563</fpage>&#8211;<lpage>1576</lpage>. <pub-id pub-id-type="doi">10.1084/jem.192.11.1563</pub-id><pub-id pub-id-type="pmid">11104799</pub-id><pub-id pub-id-type="pmcid">PMC2193092</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nishat</surname><given-names>S.</given-names></name><name name-style="western"><surname>Andreana</surname><given-names>P.</given-names></name></person-group> (<year>2016</year>). <article-title>Entirely carbohydrate-based vaccines: an emerging field for specific and selective immune responses</article-title>. <source>Vaccines</source><volume>4</volume>:<fpage>19</fpage>. <pub-id pub-id-type="doi">10.3390/vaccines4020019</pub-id><pub-id pub-id-type="pmid">27213458</pub-id><pub-id pub-id-type="pmcid">PMC4931636</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nyame</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Kawar</surname><given-names>Z. S.</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>R. D.</given-names></name></person-group> (<year>2004</year>). <article-title>Antigenic glycans in parasitic infections: implications for vaccines and diagnostics</article-title>. <source>Arch. Biochem. Biophys.</source><volume>426</volume>, <fpage>182</fpage>&#8211;<lpage>200</lpage>. <pub-id pub-id-type="doi">10.1016/j.abb.2004.04.004</pub-id><pub-id pub-id-type="pmid">15158669</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>S. N.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ayi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Serghides</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gowda</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Kain</surname><given-names>K. C.</given-names></name></person-group> (<year>2007</year>). <article-title>Disruption of CD36 impairs cytokine response to <italic toggle="yes">plasmodium falciparum</italic> glycosylphosphatidylinositol and confers susceptibility to severe and fatal malaria <italic toggle="yes">in vivo</italic></article-title>. <source>J. Immunol.</source><volume>178</volume>, <fpage>3954</fpage>&#8211;<lpage>3961</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.178.6.3954</pub-id><pub-id pub-id-type="pmid">17339496</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perraut</surname><given-names>R.</given-names></name><name name-style="western"><surname>Diatta</surname><given-names>B.</given-names></name><name name-style="western"><surname>Marrama</surname><given-names>L.</given-names></name><name name-style="western"><surname>Garraud</surname><given-names>O.</given-names></name><name name-style="western"><surname>Jambou</surname><given-names>R.</given-names></name><name name-style="western"><surname>Longacre</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2005</year>). <article-title>Differential antibody responses to <italic toggle="yes">Plasmodium falciparum</italic> glycosylphosphatidylinositol anchors in patients with cerebral and mild malaria</article-title>. <source>Microb. Infect.</source><volume>7</volume>, <fpage>682</fpage>&#8211;<lpage>687</lpage>. <pub-id pub-id-type="doi">10.1016/j.micinf.2005.01.002</pub-id><pub-id pub-id-type="pmid">15848275</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petrovsky</surname><given-names>N.</given-names></name><name name-style="western"><surname>Aguilar</surname><given-names>J. C.</given-names></name></person-group> (<year>2004</year>). <article-title>Vaccine adjuvants: current state and future trends</article-title>. <source>Immunol. Cell Biol.</source><volume>82</volume>, <fpage>488</fpage>&#8211;<lpage>496</lpage>. <pub-id pub-id-type="doi">10.1111/j.0818-9641.2004.01272.x</pub-id><pub-id pub-id-type="pmid">15479434</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pichichero</surname><given-names>M. E.</given-names></name></person-group> (<year>2013</year>). <article-title>Protein carriers of conjugate vaccines characteristics, development, and clinical trials</article-title>. <source>Hum. Vaccin. Immunother.</source><volume>9</volume>, <fpage>2505</fpage>&#8211;<lpage>2523</lpage>. <pub-id pub-id-type="doi">10.4161/hv.26109</pub-id><pub-id pub-id-type="pmid">23955057</pub-id><pub-id pub-id-type="pmcid">PMC4162048</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pinheiro</surname><given-names>R. O.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>E. F.</given-names></name><name name-style="western"><surname>Guedes</surname><given-names>H. L. D.</given-names></name><name name-style="western"><surname>Agrellos</surname><given-names>O. A.</given-names></name><name name-style="western"><surname>de Mattos</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Saraiva</surname><given-names>E. M.</given-names></name><etal/></person-group>. (<year>2007</year>). <article-title>Protection against cutaneous leishmaniasis by intranasal vaccination with lipophosphoglycan</article-title>. <source>Vaccine</source><volume>25</volume>, <fpage>2716</fpage>&#8211;<lpage>2722</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2006.05.093</pub-id><pub-id pub-id-type="pmid">16814903</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Playfair</surname><given-names>J. H. L.</given-names></name><name name-style="western"><surname>Taverne</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bate</surname><given-names>C. A. W.</given-names></name><name name-style="western"><surname>Brian de Souza</surname><given-names>J.</given-names></name></person-group> (<year>1990</year>). <article-title>The malaria vaccine: anti-parasite or anti-disease?</article-title><source>Immunol. Today</source><volume>11</volume>, <fpage>25</fpage>&#8211;<lpage>27</lpage>. <pub-id pub-id-type="pmid">2405875</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0167-5699(90)90007-v</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pulendran</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>R.</given-names></name></person-group> (<year>2011</year>). <article-title>Immunological mechanisms of vaccination</article-title>. <source>Nat. Immunol.</source><volume>12</volume>, <fpage>509</fpage>&#8211;<lpage>517</lpage>. <pub-id pub-id-type="doi">10.1038/ni.2039</pub-id><pub-id pub-id-type="pmid">21739679</pub-id><pub-id pub-id-type="pmcid">PMC3253344</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Remington</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Thulliez</surname><given-names>P.</given-names></name><name name-style="western"><surname>Montoya</surname><given-names>J. G.</given-names></name></person-group> (<year>2004</year>). <article-title>Recent developments for diagnosis of toxoplasmosis</article-title>. <source>J. Clin. Microbiol.</source><volume>42</volume>, <fpage>941</fpage>&#8211;<lpage>945</lpage>. <pub-id pub-id-type="doi">10.1128/JCM.42.3.941-945.2004</pub-id><pub-id pub-id-type="pmid">15004036</pub-id><pub-id pub-id-type="pmcid">PMC356902</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodrigues</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Acosta-Serrano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aebi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>M. A. J.</given-names></name><name name-style="western"><surname>Routier</surname><given-names>F. H.</given-names></name><name name-style="western"><surname>Schiller</surname><given-names>I.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Parasite glycobiology: a bittersweet symphony</article-title>. <source>PLoS Pathog.</source><volume>11</volume>:<fpage>e1005169</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1005169</pub-id><pub-id pub-id-type="pmid">26562305</pub-id><pub-id pub-id-type="pmcid">PMC4642930</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russell</surname><given-names>D. G.</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>J.</given-names></name></person-group> (<year>1988</year>). <article-title>Effective immunization against cutaneous leishmaniasis with defined membrane-antigens reconstituted into liposomes</article-title>. <source>J. Immunol.</source><volume>140</volume>, <fpage>1274</fpage>&#8211;<lpage>1279</lpage>. <pub-id pub-id-type="pmid">3257774</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneerson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Barrera</surname><given-names>O.</given-names></name><name name-style="western"><surname>Sutton</surname><given-names>A.</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>J. B.</given-names></name></person-group> (<year>1980</year>). <article-title>Preparation, characterization, and immunogenicity of hemophilus-influenzae type-B polysaccharide-protein conjugates</article-title>. <source>J. Exp. Med.</source><volume>152</volume>, <fpage>361</fpage>&#8211;<lpage>376</lpage>. <pub-id pub-id-type="doi">10.1084/jem.152.2.361</pub-id><pub-id pub-id-type="pmid">6967514</pub-id><pub-id pub-id-type="pmcid">PMC2185954</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schofield</surname><given-names>L.</given-names></name></person-group> (<year>2007</year>). <article-title>Rational approaches to developing an anti-disease vaccine against malaria</article-title>. <source>Microb. Infect.</source><volume>9</volume>, <fpage>784</fpage>&#8211;<lpage>791</lpage>. <pub-id pub-id-type="doi">10.1016/j.micinf.2007.02.010</pub-id><pub-id pub-id-type="pmid">17434329</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schofield</surname><given-names>L.</given-names></name><name name-style="western"><surname>Grau</surname><given-names>G. E.</given-names></name></person-group> (<year>2005</year>). <article-title>Immunological processes in malaria pathogenesis</article-title>. <source>Nat. Rev. Immunol.</source><volume>5</volume>, <fpage>722</fpage>&#8211;<lpage>735</lpage>. <pub-id pub-id-type="doi">10.1038/nri1686</pub-id><pub-id pub-id-type="pmid">16138104</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schofield</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hackett</surname><given-names>F.</given-names></name></person-group> (<year>1993</year>). <article-title>Signal transduction in host cells by a glycosylphosphatidylinositol toxin of malaria parasites</article-title>. <source>J. Exp. Med.</source><volume>177</volume>, <fpage>145</fpage>&#8211;<lpage>153</lpage>. <pub-id pub-id-type="doi">10.1084/jem.177.1.145</pub-id><pub-id pub-id-type="pmid">8418196</pub-id><pub-id pub-id-type="pmcid">PMC2190877</pub-id></mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schofield</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hewitt</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>K.</given-names></name><name name-style="western"><surname>Siomos</surname><given-names>M.-A.</given-names></name><name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name></person-group> (<year>2002</year>). <article-title>Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria</article-title>. <source>Nature</source><volume>418</volume>, <fpage>785</fpage>&#8211;<lpage>789</lpage>. <pub-id pub-id-type="doi">10.1038/nature00937</pub-id><pub-id pub-id-type="pmid">12181569</pub-id></mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schofield</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vivas</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hackett</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gerold</surname><given-names>P.</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>R. T.</given-names></name><name name-style="western"><surname>Tachado</surname><given-names>S.</given-names></name></person-group> (<year>1993</year>). <article-title>Neutralizing monoclonal antibodies to glycosylphosphatidylinositol, the dominant TNF-alpha-inducing toxin of <italic toggle="yes">Plasmodium falciparum</italic>: prospects for the immunotherapy of severe malaria</article-title>. <source>Ann. Trop. Med. Parasitol.</source><volume>87</volume>, <fpage>617</fpage>&#8211;<lpage>626</lpage>. <pub-id pub-id-type="doi">10.1080/00034983.1993.11812820</pub-id><pub-id pub-id-type="pmid">8122925</pub-id></mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seder</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>L. J.</given-names></name><name name-style="western"><surname>Enama</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Zephir</surname><given-names>K. L.</given-names></name><name name-style="western"><surname>Sarwar</surname><given-names>U. N.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>I. J.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine</article-title>. <source>Science</source><volume>341</volume>, <fpage>1359</fpage>&#8211;<lpage>1365</lpage>. <pub-id pub-id-type="doi">10.1126/science.1241800</pub-id><pub-id pub-id-type="pmid">23929949</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name></person-group> (<year>2007</year>). <source>Chemical Glycomics &#8211; From Carbohydrate Arrays to a Malaria Vaccine</source>. (<publisher-loc>Bozen</publisher-loc>).</mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>O. P.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chakravarty</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sundar</surname><given-names>S.</given-names></name></person-group> (<year>2016</year>). <article-title>Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective</article-title>. <source>Infect. Dis. Poverty</source><volume>5</volume>:<fpage>19</fpage>. <pub-id pub-id-type="doi">10.1186/s40249-016-0112-2</pub-id><pub-id pub-id-type="pmid">26951132</pub-id><pub-id pub-id-type="pmcid">PMC4782357</pub-id></mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spath</surname><given-names>G. F.</given-names></name><name name-style="western"><surname>Epstein</surname><given-names>L.</given-names></name><name name-style="western"><surname>Leader</surname><given-names>B.</given-names></name><name name-style="western"><surname>Singer</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Avila</surname><given-names>H. A.</given-names></name><name name-style="western"><surname>Turco</surname><given-names>S. J.</given-names></name><etal/></person-group>. (<year>2000</year>). <article-title>Lipophosphoglycan is a virulence factor distinct from related glycoconjugates in the protozoan parasite leishmania major</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>97</volume>, <fpage>9258</fpage>&#8211;<lpage>9263</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.160257897</pub-id><pub-id pub-id-type="pmid">10908670</pub-id><pub-id pub-id-type="pmcid">PMC16855</pub-id></mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stein</surname><given-names>K. E.</given-names></name></person-group> (<year>1992</year>). <article-title>Thymus-independent and thymus-dependent responses to polysaccharide antigens</article-title>. <source>J. Infect. Dis.</source><volume>165</volume>, <fpage>S49</fpage>&#8211;<lpage>S52</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/165-Supplement_1-S49</pub-id><pub-id pub-id-type="pmid">1588177</pub-id></mixed-citation></ref><ref id="B118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tamborrini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Mugasa</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>Y. U.</given-names></name><name name-style="western"><surname>Kamena</surname><given-names>F.</given-names></name><name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Synthetic glycosylphosphatidylinositol microarray reveals differential antibody levels and fine specificities in children with mild and severe malaria</article-title>. <source>Bioorg. Med. Chem.</source><volume>18</volume>, <fpage>3747</fpage>&#8211;<lpage>3752</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2010.04.059</pub-id><pub-id pub-id-type="pmid">20471845</pub-id></mixed-citation></ref><ref id="B119"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tillett</surname><given-names>W. S.</given-names></name><name name-style="western"><surname>Francis</surname><given-names>T.</given-names></name></person-group> (<year>1929</year>). <article-title>Cutaneous reactions to the polysaccharides and proteins of pneumococcus in lobar pneumonia</article-title>. <source>J. Exp. Med.</source><volume>50</volume>, <fpage>687</fpage>&#8211;<lpage>U152</lpage>. <pub-id pub-id-type="doi">10.1084/jem.50.5.687</pub-id><pub-id pub-id-type="pmid">19869655</pub-id><pub-id pub-id-type="pmcid">PMC2131649</pub-id></mixed-citation></ref><ref id="B120"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tinto</surname><given-names>H.</given-names></name><name name-style="western"><surname>D'Alessandro</surname><given-names>U.</given-names></name><name name-style="western"><surname>Sorgho</surname><given-names>H.</given-names></name><name name-style="western"><surname>Valea</surname><given-names>I.</given-names></name><name name-style="western"><surname>Tahita</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Kabore</surname><given-names>W.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial</article-title>. <source>Lancet</source><volume>386</volume>, <fpage>31</fpage>&#8211;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(15)60721-8</pub-id><pub-id pub-id-type="pmid">25913272</pub-id><pub-id pub-id-type="pmcid">PMC5626001</pub-id></mixed-citation></ref><ref id="B121"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Topuzogullari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Koc</surname><given-names>R. C.</given-names></name><name name-style="western"><surname>Isoglu</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Bagirova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Akdeste</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Elcicek</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Conjugation, characterization and toxicity of lipophosphoglycan-polyacrylic acid conjugate for vaccination against leishmaniasis</article-title>. <source>J. Biomed. Sci.</source><volume>20</volume>:<fpage>35</fpage>. <pub-id pub-id-type="doi">10.1186/1423-0127-20-35</pub-id><pub-id pub-id-type="pmid">23731716</pub-id><pub-id pub-id-type="pmcid">PMC3682889</pub-id></mixed-citation></ref><ref id="B122"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsai</surname><given-names>Y. H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X. Y.</given-names></name><name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name></person-group> (<year>2012</year>). <article-title>Chemical biology of glycosylphosphatidylinositol anchors</article-title>. <source>Angew. Chem. Int. Ed.</source><volume>51</volume>, <fpage>11438</fpage>&#8211;<lpage>11456</lpage>. <pub-id pub-id-type="doi">10.1002/anie.201203912</pub-id><pub-id pub-id-type="pmid">23086912</pub-id></mixed-citation></ref><ref id="B123"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Varki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lowe</surname><given-names>J. B.</given-names></name></person-group> (<year>2009</year>). <source>Biological Roles of Glycans. Essentials of Glycobiology</source>, eds <person-group person-group-type="editor"><name name-style="western"><surname>Varki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>R. D.</given-names></name><name name-style="western"><surname>Esko</surname><given-names>J. D.</given-names></name><etal/></person-group><publisher-loc>Harbor, NY</publisher-loc>: <publisher-name>Cold Spring Harbor</publisher-name>.<pub-id pub-id-type="pmid">20301233</pub-id></mixed-citation></ref><ref id="B124"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Velez</surname><given-names>I. D.</given-names></name><name name-style="western"><surname>Gilchrist</surname><given-names>K.</given-names></name><name name-style="western"><surname>Arbelaez</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Rojas</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Puerta</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Antunes</surname><given-names>C. M. F.</given-names></name><etal/></person-group>. (<year>2005</year>). <article-title>Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia</article-title>. <source>Trans. R. Soc. Trop. Med. Hyg.</source><volume>99</volume>, <fpage>593</fpage>&#8211;<lpage>598</lpage>. <pub-id pub-id-type="doi">10.1016/j.trstmh.2005.04.002</pub-id><pub-id pub-id-type="pmid">15893351</pub-id></mixed-citation></ref><ref id="B125"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vliegenthart</surname><given-names>J. F. G.</given-names></name></person-group> (<year>2006</year>). <article-title>Carbohydrate based vaccines</article-title>. <source>FEBS Lett.</source><volume>580</volume>, <fpage>2945</fpage>&#8211;<lpage>2950</lpage>. <pub-id pub-id-type="doi">10.1016/j.febslet.2006.03.053</pub-id><pub-id pub-id-type="pmid">16630616</pub-id></mixed-citation></ref><ref id="B126"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weintraub</surname><given-names>A.</given-names></name></person-group> (<year>2003</year>). <article-title>Immunology of bacterial polysaccharide antigens</article-title>. <source>Carbohydr. Res.</source><volume>338</volume>, <fpage>2539</fpage>&#8211;<lpage>2547</lpage>. <pub-id pub-id-type="doi">10.1016/j.carres.2003.07.008</pub-id><pub-id pub-id-type="pmid">14670715</pub-id></mixed-citation></ref><ref id="B127"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wessels</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Paoletti</surname><given-names>L. C.</given-names></name><name name-style="western"><surname>Rodewald</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Michon</surname><given-names>F.</given-names></name><name name-style="western"><surname>Difabio</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>H. J.</given-names></name><etal/></person-group>. (<year>1993</year>). <article-title>Stimulation of protective antibodies against type-Ia and type-Ib group-B streptococci by a type-Ia polysaccharide-tetanus toxoid conjugate vaccine</article-title>. <source>Infect. Immun.</source><volume>61</volume>, <fpage>4760</fpage>&#8211;<lpage>4766</lpage>. <pub-id pub-id-type="pmid">8406875</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.61.11.4760-4766.1993</pub-id><pub-id pub-id-type="pmcid">PMC281231</pub-id></mixed-citation></ref><ref id="B128"><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>WHO</collab></person-group> (<year>2013a</year>). <source>Malaria Vaccine Technology Roadmap</source>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(13)62238-2</pub-id><pub-id pub-id-type="pmid">24239252</pub-id></mixed-citation></ref><ref id="B129"><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>WHO</collab></person-group> (<year>2013b</year>). <source>World Malaria Report 2013</source>. World Malaria Report 2013, 1-255.</mixed-citation></ref><ref id="B130"><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>WHO</collab></person-group> (<year>2014</year>). <source>WHO 2014 World Malaria Report</source>. WHO 2014 World Malaria Report.</mixed-citation></ref><ref id="B131"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>WHO</collab></person-group> (<year>2016a</year>). Available online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.who.int/immunization/research/development/malaria_vaccine_qa/en/">http://www.who.int/immunization/research/development/malaria_vaccine_qa/en/</ext-link></mixed-citation></ref><ref id="B132"><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>WHO</collab></person-group> (<year>2016b</year>). <source>Malaria Vaccine</source>. WHO position paper - January 2016.</mixed-citation></ref><ref id="B132a"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>WHO</collab></person-group> (<year>2017</year>). <source>Leishmaniasis - The Disease and its Epidemiology</source>. Retrieved from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.who.int/leishmaniasis/disease_epidemiology/en">http://www.who.int/leishmaniasis/disease_epidemiology/en</ext-link></mixed-citation></ref><ref id="B133"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y. G.</given-names></name><name name-style="western"><surname>deGoma</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ohdan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bracy</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y. X.</given-names></name><name name-style="western"><surname>Iacomini</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>1998</year>). <article-title>Tolerization of anti-Gal alpha 1-3Gal natural antibody-forming B cells by induction of mixed chimerism</article-title>. <source>J. Exp. Med.</source><volume>187</volume>, <fpage>1335</fpage>&#8211;<lpage>1342</lpage>. <pub-id pub-id-type="doi">10.1084/jem.187.8.1335</pub-id><pub-id pub-id-type="pmid">9547344</pub-id><pub-id pub-id-type="pmcid">PMC2212239</pub-id></mixed-citation></ref><ref id="B134"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yilmaz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Portugal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tuan Tran</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gozzelino</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Gut microbiota elicits a protective immune response against malaria transmission</article-title>. <source>Cell</source><volume>159</volume>, <fpage>1277</fpage>&#8211;<lpage>1289</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2014.10.053</pub-id><pub-id pub-id-type="pmid">25480293</pub-id><pub-id pub-id-type="pmcid">PMC4261137</pub-id></mixed-citation></ref><ref id="B135"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zimmermann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lepenies</surname><given-names>B.</given-names></name></person-group> (<year>2015</year>). <article-title>Glycans as vaccine antigens and adjuvants: immunological <italic toggle="yes">Considerations</italic></article-title><volume>1331</volume>, <fpage>11</fpage>&#8211;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4939-2874-3_2</pub-id><pub-id pub-id-type="pmid">26169732</pub-id></mixed-citation></ref><ref id="B136"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zinkernagel</surname><given-names>R. M.</given-names></name></person-group> (<year>2003</year>). <article-title>On natural and artificial vaccinations</article-title>. <source>Annu. Rev. Immunol.</source><volume>21</volume>, <fpage>515</fpage>&#8211;<lpage>546</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.immunol.21.120601.141045</pub-id><pub-id pub-id-type="pmid">12500980</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>